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Summary 
 
The 2013 "EU Industrial R&D Investment Scoreboard" (the Scoreboard) contains economic 
and financial data for the world's top 2000 companies ranked by their investments in 
research and development (R&D). The sample contains 527 companies based in the EU and 
1473 companies based elsewhere. The Scoreboard data are drawn from the latest available 
companies' accounts, i.e. usually the fiscal year 2012 or 2012/13
1.  
 
Key messages  
Trends observed show a significant variation in R&D investment and economic results across 
industries and sectors. This reflects persistent market uncertainties, in particular regarding 
the uneven potential for growth of international markets and the macroeconomic 
background. More salient facts observed from the analysis of 2012 and historic company 
data since 2003 include: 
•  A general remarkable resilience of R&D investment growth from top world R&D investors, 
in a period of economic uncertainty. 
•    The 527 EU companies featuring among the top world 2000 R&D investors in 2012 
increased their investment in R&D by 6.3%, above world average (6.2%) but below the 
growth of their US counterparts (8.2%). EU overall positive numbers are largely driven by 
the R&D growth rates of German companies, particularly in the Automobile sector.  
•  Volkswagen with €9.5bn invested in R&D leads the world R&D ranking. In second place is 
Samsung Electronics (€8.3bn) from South Korea. 
•  In addition to a good performance in the Automobiles & Parts sector, EU-based 
companies outperformed the R&D growth of their US counterparts in Industrial 
Engineering (12.3% vs. 9.4%) and Aerospace & Defence (9.5% vs. -1.3%). 
•  The US continues to increase its specialisation in the high R&D-intensive sectors of ICT 
and health. Among the top 100 R&D investors, five ICT companies based in the US are 
among the best performers (increasing R&D and sales by more than 200% from 2004 to 
2013). In the biotech sector, nine of the top ten companies are based in this country. 
•  An analysis of foreign direct investments (FDI) by the companies in the world R&D ranking 
shows that the EU plays, together with the US, a major role in the international 
investment scenario, both as a source and destination of cross-border R&D activities. 
From 2003 to 2012, the EU attracted 22% of FDI projects on R&D from the set of non-EU 
companies. 
                                                       
1 However, due to differences in accounting practices, the sampling period includes a range of dates from 2011 to early 2013  (see annex on methodological 
notes).  
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Top world R&D investors continued to increase their investment efforts in research and 
development significantly (6.2%) in 2012. This happened in a global context marked by a 
general slow-down of net sales growth (4.2% vs. 9.9% in 2011) and a decline in operating 
profits (-10.1%).  
 
During the three years following the financial crisis in 2008-2009, Scoreboard companies 
increased their R&D investments by an average 6.2% per year (2010-2012). This resilience of 
companies' R&D investments during a period of economic uncertainty reflects the strategic 
importance that companies attach to such investment. Figure S1 below shows the longer-
term R&D trends for a subset of Scoreboard companies with available data for the past nine 
years. 
 
 
 
Figure S1. One-year R&D investment and net sales growth in the Scoreboard. 
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Note: For 1496 out of the top world 2000 companies in the Scoreboard with data for the whole period.  
Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD. 
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The 527 EU companies featuring among the top world 2000 R&D investors in 2012 are good 
exponents of sustained R&D focus in a challenging environment.  
 
Their R&D growth rate of 6.3% in 2012 is above the 4.3% growth rate of net sales, in a context of 
sharp profit decreases (-18.4%). This R&D growth rate is lower than that of their US counterparts 
(8.2%), which experienced a stronger slow-down of net sales (2.9%).  
Following a much slower recovery after the crisis, in 2012 top Japanese R&D investors showed 
some signs of recovery in net sales and profits, which are still not reflected in R&D growth figures 
(0.4%). Companies in the rest of the world continued to show high levels of R&D growth (8.8%). 
For the EU, the US and Japan, respectively, figures S2-S4 below show the longer-term R&D 
trends for subsets of Scoreboard companies with available data for the past nine years. 
 
 
Figure S2. One-year R&D investment and net sales growth by EU companies. 
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 European Commission, JRC/DG RTD. 
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Figure S3. One-year R&D investment and net sales growth by US companies. 
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Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD. 
Figure S4. One-year R&D investment and net sales growth by Japanese companies. 
 
-15%
-10%
-5%
0%
5%
10%
15%
20%
2012 2011 2010 2009 2008 2007 2006 2005
n
o
m
i
n
a
l
 
g
r
o
w
t
h
R&D investment
net sales
Note: For 324 out of the top Japanese 353 companies in the Scoreboard with data for the whole period.  
Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD.  
 
The 2013 EU Industrial R&D Investment Scoreboard 9
 
 
For the first time since 2004, a company based in the EU leads the world R&D ranking:  The 
German carmaker Volkswagen, with €9.5bn invested in R&D. Samsung Electronics from South 
Korea jumps to the second place. 
 
The other companies in the top ten include five from the US (three pharma and two ICT), two 
from Switzerland (both pharma) and one from Japan (automobile). Most of the 100 top 
companies showing the largest R&D increases continue to be, as in 2011, in the Automobiles & 
Parts and in the ICT sectors: e.g. Tata Motors, India (77.6%);  Fiat, Italy (51.5%); 3M, the US 
(57.7%);  Western Digital, the US (49.0%); Apple, the US (39.2%); Volkswagen, Germany 
(32.1%); Qualcomm, the US (30.7%), Huawei, China (30.3%), Google, the US (27.7%). Some of 
these companies have increased R&D partly as a result of acquisitions. 
 
The top 50 companies of the Scoreboard are mainly from Automobiles & Parts, 12 (13 in 2004), 
ICT industries, 14 (13 in 2004) and Pharmaceuticals and Biotechnology, 15 (11 in 2004). These 
companies are based in the EU, 16 (18 in 2004), the US, 19 (17 in 2004) and Japan, 11 (same as 
in 2004).  
 
Among the top 100 R&D investors, five ICT companies based in the US are among the best 
performers (in terms of R&D and sales growth) over the last ten years: Google (Internet), Oracle 
(Software), Qualcomm (Telecom equipment), Apple (Computer Hardware) and Broadcom 
(semiconductors). 
 
The performance of EU companies compared to US companies in the ICT sectors varies by sub-
sector...  
 
Despite lagging behind the US in the volume of R&D investments and in the number of 
companies, EU-based Scoreboard companies in the Software and Computer Services sector 
s h o w  v e r y  s t r o n g  p e r f o r m a n c e :  1 4 . 2 %  i n  R & D  g r o w t h ,  c o u p l e d  w i t h  9 . 7 %  g r o w t h  i n  s a l e s  
(against 12.6% and 6.9% respectively for the US). This contrasts with negative figures in the 
Technology Hardware & Equipment sector for EU companies (-2.3% in R&D and -9.3% in sales); 
very positive developments (14.8% and 6.8% respectively) are observed for US ones. 
 
… while in the Automobiles & Parts, Industrial Engineering and Aerospace & Defence sectors, 
EU-based companies clearly outperform their US counterparts. 
 
EU companies in the Automobiles & Parts sector, led by German carmakers in particular, show 
very high increases in R&D investment and sales (14.2% and 11.3% respectively). The R&D 
growth rates of Volkswagen (32.1%), BMW (17.2%) and Robert Bosch (17%) determine a large 
portion of German and EU overall positive numbers. The opposite holds true for US-based 
Automobiles & Parts companies (-2.6% for R&D and 0% for sales growth), still recovering from 
the crisis and the US government bail-outs of GM and Chrysler (now owned by Fiat). In the case 
of the Aerospace & Defence sector, strong regional differences in performance are also 
observed in favour of the EU: increases of 9.5% in R&D and 8.3% in sales (against -1.3% and 
6.7% respectively in the US). 
 
The above-described divergent sectoral performances in the EU and US regions observed in 
2012 point to a reinforcement of their relative specialisation: towards medium-high R&D-
intensive sectors in the EU and towards high R&D-intensive sectors in the US (see figure S5).  
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Trends observed in the pharmaceutical and biotechnology subsectors illustrate well the 
reinforcement of the US specialisation towards high-tech intensive sectors. 
 
While in 2012 the performance of the pharmaceutical and biotech sector in the US slowed down, 
showing the negative effect of the expiration of several of their blockbuster patents (4.3% in R&D 
but -0.3% in sales, compared with 3.2% and 2.8% respectively in the EU), the trend over the last 
ten years shows that the EU-US R&D investment gap in this sector is maintained (see figure S6). 
  
A more detailed analysis of the therapeutic biotechnology subsector (expected to contribute with 
up to 50% of new drugs by 2018) shows the dominance of the US: eight of the top ten companies 
in terms of R&D growth and profitability are based in that country. However, evidence shows that 
there are a number of examples of EU companies which show both high performance and the 
ability to grow to a sustainable size through well-chosen collaborations, mainly with large 
pharmaceutical counterparts.  
 
 
 
Figure S5. R&D investment of EU and US companies by sector group. 
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An analysis of foreign direct investments (FDI) by the companies in the world R&D ranking 
shows that the EU attracted 22% of FDI projects on R&D from the set of non-EU companies. 
 
The EU, together with the US, plays a major role in the international investment scenario, both as 
a source and destination of knowledge-intensive FDIs. From 2003 to 2012, the EU attracted 22% of 
FDI projects on R&D from the set of non-EU companies while the US received only a share of 8 % 
(see figure S7). Six out of the ten countries with the highest number of international projects are 
European.  
FDIs in R&D are concentrated mainly in 3 sectors: IT Hardware, Automobiles & Parts, and 
Pharmaceuticals & Biotechnology. 
 
Figure S6.  Relative size of EU R&D in Pharma and Biotech compared to US 
 
Source: The 2013 EU Industrial R&D Investment Scoreboard European Commission, JRC/DG RTD. 
Note: The relative size has been calculated as the ratio of sector R&D expenditures in EU over US considering 
the 136 companies with R&D data for the whole period.  
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Figure S7.    Inflows of FDIs in R&D  by main world regions 2003-2012 
 
Data: FT fDi Markets database. 
 
Source: The 2013 EU Industrial R&D Investment Scoreboard European Commission, JRC/DG RTD. 
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Introduction 
 
In 2013, we continued implementing changes in the “EU Industrial R&D Investment 
Scoreboard” (the Scoreboard)
2 aiming to enhance its capacity to monitor and analyse 
worldwide trends in industrial R&D. For background information on the Scoreboard please 
see Annex 1. 
The scope of the Scoreboard has improved progressively, increasing the geographic and time 
coverage and the number of companies. The target is to cover fast-growing medium-sized 
companies, particularly those in key sectors such as health and the ICT-related industries. 
Thus far, the total R&D investment of companies included in the Scoreboard is equivalent to 
more than 90% of the total expenditure on R&D by businesses worldwide
3.  
In this year's edition, the Scoreboard includes the 2000 companies investing the largest 
sums in R&D in the world while maintaining an EU focus by complementing this coverage 
with the inclusion of the top 1000 R&D investing companies based in the EU
4.  
The Scoreboard collects key information to enable the R&D and economic performance of 
companies to be assessed. The main indicators, namely R&D investment, net sales, capital 
expenditures, operating profits and number of employees are collected following the same 
methodologies, definitions and assumptions applied in previous years. This ensures 
comparability so that the companies' economic and financial data can be analysed over a 
longer period of time.  
For the second year, data are now being collected by Bureau van Dijk Electronic Publishing 
GmbH, following basically the same approach and methodology applied since the first 
Scoreboard edition in 2004. Please see the main methodological limitations summarised in 
Box 1 and detailed methodological notes in Annex 2. 
The capacity of data collection is being improved by gathering information about the 
ownership structure of the Scoreboard parent companies and the main indicators for their 
subsidiaries. This will allow a better characterisation of companies, in particular regarding 
the sectoral and geographic distribution of their research and production activities and the 
related patterns of growth and employment. 
Companies' behaviour and performance can be analysed over longer time periods using our 
history database that contains information on the top R&D companies since 2003. This 
enables benchmarking analyses of companies across sectors and countries, for example the 
identification of companies showing outstanding economic or innovation results and the 
analysis of the main factors underlying such successful dynamics. 
In this year's edition of the Scoreboard, companies' R&D rankings are based on information 
taken from the companies’ latest published accounts. For most companies these correspond 
to calendar year 2012, but a significant proportion have financial years ending on 31 March 
2013. There are few companies included with financial years ending as late as end June 2013 
and a few for which only accounts to end 2011 were available. 
                                                       
2  The EU Industrial R&D Investment Scoreboard is published annually by the European Commission (JRC-IPTS/DG RTD) as part of its Industrial Research 
and Innovation Monitoring and Analysis activity (IRIMA).  
3  According to the latest figures reported by Eurostat, i.e. BERD financed by the business enterprise sector in 2009 compared with R&D figures in the 2010 
Scoreboard. 
4  In this report, the term EU company refers to companies whose ultimate parent has its registered office in a Member State of the EU. Likewise, non-EU 
company applies when the ultimate parent company is located outside the EU (see also the glossary and definitions in Annex 2 as well as the handling of 
parent companies and subsidiaries).  
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This report concentrates on the analysis of the world's top 2000 companies that all 
invested more than €22.6 million in R&D in 2012. The sample comprises companies based 
in the EU (527), the US (658), Japan (353) and other countries (462) including China, 
Taiwan, South Korea, Switzerland, the Cayman Islands, India, Canada, Australia, Israel, 
Norway, Bermuda, Brazil and a further 13 countries.  A sample consisting of the top 1000 
R&D investing companies based in the EU is analysed separately in chapter 4; these all 
have R&D investments exceeding €5.2 million. 
The characteristics of the sample of 2000 companies used for most of the analysis are 
summarised in Table 1. 
The sector and country composition of the EU 1000 sample is found in Annex 3.  
This edition shows that companies continued to increase R&D investments in 2012 at a 
significant pace, higher than the growth rate of revenues. This report also shows a great 
variety in company R&D and economic patterns across industries and between countries, 
reflecting important differences in market conditions and economic background throughout 
the world.  
 
Report structure  
Chapter 1 presents the worldwide trends of industrial R&D. It provides an overview of the 
main indicators for the top 2000 companies ranked by level of R&D investment and the main 
changes that took place over the last year. An analysis of the main indicators of the company 
data aggregated by world regions is included together with the performance of companies 
over the period 2004-2012. 
The performance of individual companies among the top R&D investors is provided in 
chapter 2. The list of the top world 100 R&D companies is examined highlighting those 
companies showing remarkable R&D and economic results and improvement in the R&D 
ranking over the last 10 years. 
Chapter 3 presents an analysis of the main R&D and economic indicators of companies 
aggregated by industrial sector, with comparisons of EU companies and their main 
worldwide counterparts.  
Chapter 4 discusses the trends on R&D and economic performance of the companies 
included in the extended sample comprising the top 1000 R&D investors based in Member 
States of the EU.  
Chapter 5 focuses on the analysis of R&D-led trends on health and biotechnology and the 
behaviour of the main industrial players included in the Scoreboard over the past 10 years. 
The chapter includes the identification of most successful companies in this field and the 
comparison across countries and regions.  
Finally, chapter 6 presents an analysis based on data about foreign direct investments (FDIs) 
made by the Scoreboard companies. It covers FDIs committed to R&D projects as well as to 
production facilities and other industrial activities. It includes a comparison of companies' 
FDI strategies across sectors and countries.   
Annex 1 provides background and methodological information about how the Scoreboard is 
prepared. The methodological approach of the Scoreboard, its scope and the limitations are  
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described in Annex 2 and the listing of companies ranked by their level of R&D investment is 
provided in Annex 3.   
The complete data set is freely accessible online at: 
http://iri.jrc.ec.europa.eu/scoreboard13.html 
In the next edition, this website will allow user-friendly and interactive access to the 
individual company data or to groups of companies aggregated by industrial sector and 
country.    
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Table 1.  Profile of the 2013 Scoreboard . 
         2000 companies with R&D investment above €22.6 million 
527 companies based in the EU 
Companies 
by country 
Germany 130;  United Kingdom 107;   France 75;   Sweden 40;   Netherlands 
35;  Italy 30;  Denmark 25;    Finland 20;   Spain 16;  Belgium 13;  Austria 12; 
Ireland 11; Luxembourg 4 ; Portugal 4 ; Czech Republic 1 ; Greece 1;  
Hungary 1; Malta 1; Slovakia 1  
The 10 most 
numerous 
sectors  
Industrial Engineering 62; Pharmaceuticals & Biotechnology 58; Electronic & 
Electrical Equipment 38;  Software & Computer Services 37;  Automobiles & 
Parts 36; Technology Hardware & Equipment 29; Chemicals 24; Banks 23; 
Health Care Equipment & Services 20; Aerospace & Defence 18. The top 5 
sectors account for 43.8% of the 527. 
1473 companies based in non-EU countries 
Companies 
by country 
US 658;   Japan 353;   China 93;  Taiwan 82;  South Korea 56;  Switzerland 54;  
Cayman Islands 49;  India 22;   Canada 17;  Australia 15;  Israel 15; Norway 
11;  Bermuda 10;  Brazil 8 and further 13 countries. 
The 10 most 
numerous 
sectors  
Technology Hardware & Equipment 264; Pharmaceuticals & Biotechnology 
156;  Software & Computer Services 151;   Electronic & Electrical Equipment 
139; Industrial Engineering 116; Chemicals 94; Automobiles & Parts 90; 
Health Care Equipment & Services 63; General Industrials 54;  Construction & 
Materials 39. The top 5 sectors account for 56.1% of the 1473. 
 
Source:   The 2013 EU Industrial R&D Investment Scoreboard. 
               European Commission, JRC/DG RTD. 
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Box 1.  Methodological caveats 
Users of Scoreboard data should take into account the methodological limitations 
summarised here,  especially when performing comparative analyses (full description of 
methodology is found in Annex 2):  
A typical problem arises when comparing data from different currency areas.  The 
Scoreboard data are nominal and expressed in Euros with all foreign currencies converted 
at the exchange rate of the year-end closing date (31.12.2012). The variation in the 
exchange rates from the previous year directly affects the ranking of companies, 
favouring those based in countries whose currency has appreciated with respect to the 
other currencies. In this reporting period, exchange rates of the Euro against main 
currencies changed less than in past years. The main currency move was due to the 
Japanese Yen that depreciated by 13.5% against the Euro, whereas the US dollar 
depreciated by less than 2.5% and the pound sterling remained practically unchanged.  
The growth rate of the different indicators for companies operating in markets with 
different currencies is affected in a different manner. In fact, companies' consolidated 
accounts have to include the benefits and/or losses due to the appreciation and/or 
depreciation of their investments abroad. The result is an 'apparent' rate of growth of the 
given indicator that understates or overstates the actual rate of change. For example, this 
year the R&D growth rate of companies based in the Euro area with R&D investments in 
Japan is partly understated because the 'losses' of their overseas investments due to the 
appreciation of the Euro against the Japanese yen (from ¥100.6 to ¥114.2). Conversely, 
the R&D growth rate of Japanese companies is partly overstated due to the 'benefits' of 
their investments in the Euro area. Similar effects of understating or overstating figures 
would happen for other indicators, e.g. for net sales.  
When analysing data aggregated by country or sector, be aware that in many cases, the 
aggregate indicator depends on the figures of a  f e w  f i r m s .  T h i s  i s  d u e ,  e i t h e r  t o  t h e  
country's or sector's small number of firms in the Scoreboard or to the indicator 
dominated by a few large firms. 
The different editions of the Scoreboard are not directly comparable because of the year-
on-year change in the composition of the sample of companies, i.e. due to newcomers 
and leavers. Every Scoreboard comprises data of several financial years allowing analysis 
of trends for the same sample of companies. 
In most cases, the companies' accounts do not include information on the place where 
R&D is actually performed; consequently the approach taken in the Scoreboard is to 
attribute each company’s total R&D investment to the country in which the company has 
its registered office. This should be borne in mind when interpreting the Scoreboard's 
country classification and analyses. 
Growth in R&D can either be organic, the outcome of acquisitions or a combination of the 
two. Consequently, mergers and acquisitions may sometimes underlie sudden changes in 
specific companies' R&D growth rates and/or positions in the rankings.  
Other important factors to take into account include the difference in the various 
countries’ (or sectors’) business cycles which may have a significant impact on companies' 
investment decisions, and the initial adoption or stricter application of the International 
Financial Reporting Standards (IFRS)
5.  
                                                       
5 Since 2005, the European Union requires all listed companies in the EU to prepare their consolidated financial statements according to IFRS (see: EC 
Regulation No 1606/2002 of the European Parliament and of the Council of 19 July 2002 on the application of international accounting standards at 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32002R1606:EN:HTML).  
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1.  Worldwide trends in corporate R&D 
 
This chapter provides an overview of changes in the main R&D and economic indicators of 
the world 2000 companies that invested more than €22.6 million in R&D in 2012
6. It 
comprises an analysis of the company data aggregated by main world region for the period 
2004-2012. 
This edition shows that companies continued to increase R&D investments in 2012 at a 
significant pace and well above the growth rate of revenues.  
Trends observed show a significant variation of R&D investment and economic results across 
industries and sectors and important differences with respect to the previous year. This 
reflects persistent market uncertainties, in particular regarding the uneven potential for 
growth of international markets and the macroeconomic background.   
Key findings 
•  The top 2000 Scoreboard companies invested in R&D 6.2% more in 2012 than in 2011, 
following the increase of 6.1% in the year before. The net sales of the 2000 companies 
increased less than R&D, at 4.2%, compared with the net sales increase of 9.9% in 2011. 
•  The 527 EU companies increased R&D investment and net sales by the significant figures 
of 6.3 % and 4.3 % respectively. The 658 US companies reported a higher increase in R&D 
(8.2 %) but a much lower increase in net sales (2.9 %). The Japanese companies continued 
to lag behind, the 353 companies based in Japan increased R&D by only 0.4% and net 
sales by 3.3%.  
•  Companies outside of the EU, the US and Japan (the OC group) continued to significantly 
increase R&D and net sales, by 8.8  % and 5.8  % respectively, but at a lower pace 
compared with previous years. The largest increases in R&D investment in this group 
were reported by companies based in China (12.2 %), South Korea (8.9 %) and Taiwan 
(8.2%). 
•  Trends over the past 8 years show that companies based in the EU and the US have 
recovered levels of R&D growth prior to the crisis whereas that of net sales, that 
recovered significantly in 2010-2011, fell well below the rate of R&D growth in 2012. 
 
 
 
1.1  Indicator changes over the last year 
The main economic and financial indicators for the year 2012 for the set of 2000 companies 
are summarised in Table 1.1.  
•  After the recovery of company results showed last year, this year's edition of the 
Scoreboard still shows a significant rise in worldwide R&D investment. The 2000 
Scoreboard companies invested €538.8 billion in R&D, 6.2% more than in 2011, 
                                                       
6 Due to data availability some companies may be missed, please see methodological limitations in Annex 2.  
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following the increase of 6.1% in the year before. Seventy per cent of the companies 
showed positive R&D growth in 2012.   
•  For the second consecutive year, the net sales of the 2000 companies increased less 
than R&D, at 4.2%, less than the net sales increase of 9.9% in 2011.  Company results in 
terms of operating profits were mixed, 82% of the companies made profits and average 
profitability was 9.2%, however the remaining companies (18%) presented strong losses. 
•  Company investment in fixed capital continued to grow at a significant pace. It increased 
by 9.6% compared with the previous year’s increase of 12.7%. Capital expenditure as a 
percentage of net sales increased slightly from 6.6% in 2011 to 7.1% in 2012. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                       
7 Compound annual growth rate. 
8 Fixed capital investment 
Table 1.1   Overall performance of the 2000 companies in the 2013 
Scoreboard.   
Factor  World-2000 
R&D investment, € bn  538.8 
One-year change, %  6.2 
CAGR
7 3yr, %  6.4 
Net Sales, € bn  16845.8 
One-year change, %  4.2 
CAGR
  3yr, %  8.5 
R&D intensity, %  3.2 
Operating profits,  € bn  1549.3 
One-year change , %  -10.1 
Profitability, %  9.2 
Capex
8, € bn  1109.1 
Capex / net sales, %  7.1 
One-year change , %  9.6 
Number of employees, million 
One-year change, % 
48.471 
1.5 
 
 
Note: Calculation of growth rates and ratios include only companies for which data 
are fully available. 
Source:   The 2013 EU Industrial R&D Investment Scoreboard. 
                European Commission, JRC/DG RTD.  
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1.2  R&D trends by world region 
 
This section analyses the overall R&D and economic performance of the Scoreboard 
companies according to the location of their registered offices in the main world regions. 
The 2000 companies are grouped into four main sets: the top 527 companies from the EU, 
658 companies from the US, 353 from Japan and 462 companies from other countries (OC). 
‘Other countries’ includes companies from China (93), Taiwan (82), South Korea (56), 
Switzerland (54), the Cayman Islands (49), India (22) and companies based in a further 19 
countries. 
Figure 1.1 and table 1.2 summarise the companies' indicators aggregated by main world 
region. Table 1.3 shows the main indicators for countries included in the OC group. 
The R&D investment and net sales for the 527 EU companies continued to grow at significant 
pace in 2012, at 6.3 % and 4.3 % respectively (slightly above the world’s average of 6.2 % and 
4.2 % respectively).  
The positive overall numbers of the EU group are largely driven by the performance of 
German companies, particularly in the Automobiles & Parts sector. The 130 German 
companies, with an R&D share of 34% in the EU group, increased R&D by 11.9% contributing 
more than 60% of the R&D growth of the EU companies.   
The group of US companies increased R&D investment significantly above the world’s 
average, at 8.2 % but net sales only grew by 2.9 % compared with a strong increase in 2011.  
Japanese companies underperformed against EU firms, both in terms of R&D and net sales, 
increasing R&D investments and net sales only by 0.4% and 3.3% respectively.  
Companies based outside of the EU, US and Japan (the OC group) substantially increased 
R&D and net sales, by 8.8  % and 5.8  % respectively, but in a lesser proportion than in 
previous years, especially in terms of net sales. The largest increase in R&D investment was 
reported by the 93 companies based in China (12.2 %), although the total R&D of these 
companies is still modest (3.0% of the total sample). Other companies in this group that 
showed large increases in R&D were companies based in the Cayman Islands (38.7%), India 
(33.1%), South Korea (8.9%) and Taiwan (8.2%). The companies based in Switzerland, the 
largest R&D investing country of the OC group (world R&D share of 4.2%) increased R&D in 
2012 by 4.3%. Two large Swiss companies, Roche and Novartis, dominate the R&D figures of 
their home country with 62% of Swiss R&D. 
Compared with last year’s Scoreboard (1500 top R&D investors), the EU companies’ share of 
total R&D investment rose by 1.2 (from 28.3 % to 29.5 %).  The share held by US companies 
increased slightly by 0.5 percentage points, companies based in other countries (OC) 
increased their share by 1.2 percentage points, while the share of Japanese companies fell 
sharply by 2.9 points.  
The average R&D intensity of the EU, US and OC companies increased due to a higher 
growth of R&D investments compared with the growth rate of net sales, especially for the 
US companies that had the lowest growth rate of net sales. On the contrary, companies 
based in Japan decreased their average R&D intensity because of their very low growth rate 
of R&D compared to that of net sales.  
Company figures for fixed capital expenditure changed significantly over the last year. 
Companies based in the EU recovered substantial levels of investment (9.8% growth)  
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compared with a slight decrease in the previous year.  The US and Japanese companies 
substantially increased their fixed capital expenditures to 11.7 % and 13.9 % respectively, 
whereas that of companies from the OC group increased at a more modest rate (5.7 %).       
Companies in three of the four regions decreased profits in 2012 with Japanese companies 
showing a 4.2% increase but the EU had the largest decrease. As a consequence of this, the 
profitability (operating profits as percentage of net sales) remained level for Japan, 
decreased a little for the US but decreased a lot for the EU (the effect of a low growth rate of 
net sales can be offset by a lower growth rate of profits). In the case of the US group of 
companies, the drop in profits partially reflects the major losses of General Motors, which 
has just emerged from bankruptcy. In fact, this year’s accounts for General Motors include a 
“goodwill impairment charge” of $27bn and related losses of $30.4bn.   
As underlined in previous editions, most of the differences in R&D intensity and profitability 
between regions and countries are related to differences in sector mix. The US is by far the 
strongest region in the group of high R&D intensity sectors including pharmaceuticals, 
health, software, and technology hardware whereas the EU and Japan are stronger in 
medium R&D intensity sectors like the automotive sector (see chapter 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  R&D investment by the top 2000 companies, by main world region (% of total 
€538.8bn) 
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Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD.  
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9 Operating profits as percentage of sales. 
Table 1.2  Overall performance of the 2000 companies in the 2013 Scoreboard. 
Factor  EU  USA  Japan  Other countries 
No. of companies  527 658 353  462 
R&D in 2012, € bn  158.0 189.4 102.7  89.4 
World R&D share, %  29.3   35.2   18.9   16.6  
One year change, %  6.3  8.2   0.4   8.8  
CAGR
 3yr, %  6.4  8.0   1.2   9.4  
 Net Sales, € bn  5974.6 3892.2 2944.0  4039.9 
One year change, %  4.3  2.9   3.3   5.8  
CAGR
 3yr, %  8.6   8.4   3.0   13.0  
R&D intensity, %  2.6  4.9   3.5   2.2  
Operating Profit, € bn  483.4 505.7 131.1  429.0 
One year change, %  -18.4   -5.5   4.2   -8.9  
Profitability
9  8.1  13.0   4.4   10.6  
Capex, € bn  361.90 231.3  195.2  320.7 
Capex intensity  7.1   6.0   6.6   8.8  
One year change, %  9.8   11.7  13.9   5.7 
Employees, million  18.357 11.138  8.206  10.770 
One year change, %  1.1 3.0 1.3  1.0 
Source:   The 2013 EU Industrial R&D Investment Scoreboard. 
               European Commission, JRC/DG RTD.  
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1.2.1  Long-term performance of companies by world region 
The annual growth rates of R&D investment and net sales and the profitability of companies 
based in the EU, the US and Japan is provided respectively in figures 1.2, 1.3 and 1.4 for the 
period 2004-2012. These figures are based on our history database comprising R&D and 
economic indicators over the whole 2004-2012 period for 1017 companies (EU 248, US 358 
and Japan 241). 
 
The trends observed in these figures show the behaviour of these companies including the 
effects of the crisis that began in 2008. The following points are observed: 
•  In terms of R&D growth, companies based in the EU and the US seem to have 
recovered to the levels prior to the crisis, whereas Japanese companies lag behind, 
probably because of special adverse factors such as the earthquake. 
•  The growth rate of net sales for companies based in the EU and the US was hit hard 
by the crisis in 2008-2009 but recovered strongly in 2010-2011 with EU companies 
outperforming US firms in 2012. Net sales of companies from Japan were somewhat 
less affected by the crisis in 2008-2009 but have shown a slow recovery in the past 
two years. 
•  Performance in terms of profitability show that US-based companies recover more 
rapidly from the crisis and have higher levels of profitability than their EU 
counterparts and are especially higher than the Japanese ones. 
Table 1.3  Overall performance of companies based in the largest countries of the OC 
(other countries) group in terms R&D. 
Factor  Switzerland  South Korea  China  Taiwan 
 OC 
group 
No. of companies  54 57  93  82  462 
R&D in 2012, € bn  22.4 17.5  16.1  9.3  89.4 
World R&D share  4.2 3.3  3.0  1.7  16.6 
One year change, %  4.3 8.9  12.2  8.2  8.8 
CAGR
  3yr, %  0.8 7.5  22.9  8.9  9.4 
R&D intensity  6.4 2.2  1.4  2.2  2.2 
Profitability  15.4 6.6 6.6  3.4  10.6 
Employees, thousand  1375.8 1.6*  4152.2  2112.0  10770.0 
One year change, % 
5.1 
 
-77.3* 
 
-0.4 
 
-1.8 
 
1.0 
 
* Many South Korean companies do not report number of employees. 
Source:   The 2013 EU Industrial R&D Investment Scoreboard. 
                 European Commission, JRC/DG RTD.  
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Figure 1.2.    One-year R&D investment and net sales growth and profitability by the EU 
companies. 
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Note: for 388 EU out of the 2000 companies with R&D and net sales data for the whole period  
Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD. 
Figure 1.3.    One-year R&D investment and net sales  growth and profitability by the US 
companies. 
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Note: for 547 US  out of the 2000 companies with R&D and net sales data for the whole period  
Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD.  
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1.2.2  R&D trends by world regions and sector groups   
 
Trends in R&D over the long-term are presented in figure 1.5 for the main world regions. The 
figures refer to a set of companies that reported R&D over the whole period 2004-2012 (1559 
companies: EU 352, US 564, Japan 332 and rest of the world 311). The R&D data are broken down 
into groups of industrial sectors with characteristic R&D intensities (see definition in Box 1.1).  
The following points can be observed regarding the overall R&D changes in the period 2004-2012 
(figure 1.6):  
•  The world 1559 companies increased R&D by 50.8% (EU-352 44.4%; US-5643 66.2%; Japan-332 
11.6% and rest of the world-311 124.8%). 
•  For the 352 EU companies, the main R&D increases were in low R&D-intensive sectors (50.3%) 
and medium-low sectors (46.6%).    
•  For the 564 US companies, the main R&D increases were in medium-low R&D-intensive sectors 
(125.7%) and high sectors (79.7%).  
•  For the 332 Japanese companies, the main R&D increases were in medium-high R&D-intensive 
sectors (12.8%) and high sectors (12.3%).  
•  For the 311 companies based in the rest of the world, the main R&D increases were in low 
R&D-intensive sectors (276.7%) and high sectors (129.1%).  
 
 
Figure 1.4.   One-year R&D investment and net sales growth and profitability by the 
Japanese  companies. 
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Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD.  
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Box 1.1.    Grouping of industrial sectors according to R&D intensity (R&D    as % of net 
sales) 
High R&D intensity sectors (intensity above 5%) include e.g. Pharmaceuticals & 
biotechnology; Health care equipment & services; Technology hardware & equipment; 
Software & computer services and Aerospace & defence. 
Medium-high R&D intensity sectors (between 2% and 5%) include e.g. Electronics & 
electrical equipment; Automobiles & parts; Industrial engineering & machinery; Chemicals; 
Personal goods; Household goods; General industrials; Support services. 
Medium-low R&D intensity sectors (between 1% and 2%) include e.g. Food producers; 
Beverages; Travel & leisure; Media; Oil equipment; Electricity; Fixed line 
telecommunications. 
Low R&D intensity sectors (less than 1%) include e.g. Oil & gas producers; Industrial metals; 
Construction & materials; Food & drug retailers; Transportation; Mining; Tobacco; Multi-
utilities. 
Figure 1.5  R&D investment trends by the Scoreboard companies for main world regions
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Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD.  
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1.2.3  Employment trends by regions and sector groups 
 
The companies listed in this year's Scoreboard employed 48.471 million people in 2012, 1.5% more 
than the previous year. The distribution of employees by region was 18.357 million in the 527 
companies based in the EU, 11.138 million in the 658 US companies, 8.206 million in the 353 
Japanese companies and 10.770 million in the 462 companies from other countries (1827 out of 
the 2000 companies reported number of employees). 
 
Trends on employment over the long-term are presented in figure 1.6 for the main world regions. 
The figures refer to a set of companies that reported number of employees over the whole period 
2004-2012 and are broken down into groups of industrial sectors with characteristic R&D 
intensities (see definition in Box 1.1).  
 
The following points can be observed regarding the changes in number of employees in the period 
2004-2012 (figure 1.6):  
•  Overall worldwide employment increased by 27.9 % from 2004 to 2012 led by increases in high 
R&D-intensive sectors (42.0 %) and medium-high sectors (29.9 %). 
•  For the EU companies, the overall employment growth was 22.6 %, increasing by 49.2 % in high 
R&D-intensive sectors, by 24.2% in medium-high and by 18.5% in low sectors. 
•  For the US companies, the overall employment growth (25.1 %) greatly varies by sector group: 
a strong increase for high R&D-intensive sectors (43.7 %) and a sharp decrease in low-tech 
sectors (-23.2 %). 
•  For the Japanese companies, the overall employment increase of 24.0 % corresponded to an 
increase of 31.4 % in low R&D-intensive sectors and of 28.5 % in medium-high sectors. 
•  The ratio of employment in high to medium-high R&D intensity sectors for companies based in 
Japan fell from 38% to 32%, rose slightly for EU companies, from 29% to 35%, and went up a lot 
for US companies from 80% to 98%. This illustrates the way high R&D-intensive sectors in the 
US have been growing rapidly while medium-high sectors such as the automotive sector are 
slowly going down the rankings. 
 
It is important to remember that data reported by the Scoreboard companies do not inform about 
the actual geographic distribution of the number of employees. A detailed geographic analysis 
should take into account the location of subsidiaries of the parent Scoreboard companies as well 
as the location of other production activities involved in the value-chains. 
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Figure 1.6  Employment trends by the Scoreboard companies for main world regions. 
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2. Top R&D investing companies 
This chapter describes the performance of individual companies, with a focus on the results 
of top R&D investors, highlighting those companies that show considerable changes in 
economic performance, in particular from an R&D viewpoint. 
The world's top 100 R&D companies are analysed, highlighting those presenting important 
changes from the previous year and those showing the best performance in terms of R&D 
and economic growth over the last 10 years. This year's R&D ranking of the top 50 
companies is presented in figure 2.1 and table 2.1 shows changes in such ranking since the 
first Scoreboard in 2004. 
 
 
 
Key findings 
 
•  The top R&D investor is the German company Volkswagen, which was in 3
rd place last 
year and in 6
th place the year before. In 2
nd position is Samsung Electronics from South 
Korea with Microsoft from the US 3
rd.  The other companies in the top-ten include four 
from the US, two from Switzerland and one from Japan. 
•  Results of the top 100 companies, accounting for 54.6 % of the total R&D investment by 
the 2000 companies, confirm the continued recovery of industrial R&D investment. Of 
these 100 companies, 72 increased R&D investment (vs. 75 in 2011), including 30 
companies with double-digit R&D growth; of the 28 that decreased R&D, 7 decreased by 
a double digit percentage. Regarding net sales, 64 companies reported an increase (vs. 71 
in 2011), including 25 companies with double-digit sales growth. 
•  The top 100 group includes: 
-  28 EU companies of which 19 have increased R&D (10 by more than 10%),  
-  37 US companies of which 31 increased R&D (11 by more than 10%),  
-  22 from Japan of which 10 increased R&D (4 by more than 10%) and  
-  14 companies from other countries of which 12 increased R&D (5 by more than 10%). 
•  The companies showing the largest increase in R&D are Tata Motors, India (77.6%); 3M, 
US (57.7%); FIAT, Italy (51.5%); Western Digital, US (49.0%); Gilead Sciences, US (46.4%).  
Those showing the largest decrease in R&D are Renesas, Japan (-24.9%); Hitachi, Japan (-
17.3%); Boeing, US (-17.1%); Nokia, Finland (-15.1%); Pfizer, US (-14.0%). 
•  Among the top 100 group, 30 companies have at least doubled their net sales since 2004 
(8 companies based in the EU and 13 from the US). This group of companies is mainly 
from high R&D-intensive sectors (18); 27 of them have increased R&D by more than 100% 
and 15 companies increased employment by more than 100%. A number of the large 
increases are for companies that have made substantial acquisitions. 
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General trends 
 
In the 2013 Scoreboard 111 companies have an R&D investment of more than € 1.0bn (31 
from the EU and 40 from the US) while 55 have R&D exceeding € 2.0bn (18 from the EU and 
21 from the US). 
The top 10 companies invested more than € 5bn in R&D and account for 13.3 % of the total 
R&D investment by the 2000 Scoreboard companies. 
This year, the top R&D investor is the German company Volkswagen (€ 9.5bn) which was 
third last year and sixth in 2010
10. There are five US companies in the top ten: Microsoft 
(€7.9bn), Intel (€7.7bn), Merck US (€6.0bn), Johnson & Johnson (€5.8bn) and Pfizer (€5.7bn). 
The other companies in the top ten are Roche (€  7.0bn) and Novartis (€  6.9bn) from 
Switzerland, Samsung Electronics (€8.3bn) from South Korea and Toyota Motor (€7.1bn) 
from Japan. 
The top 100 companies invested € 295.4 billion, accounting for 54.6 % of the total R&D 
investment by all the 2000 Scoreboard companies, although accounting for only 27.1% of the 
total net sales of the sample. The EU has 28 companies among the top 100 R&D investors, 
one company less than it had in the 2012 Scoreboard. The US has 36 companies, two more 
than it had last year and Japan has 22, three companies less than in last year’s Scoreboard. 
The EU companies in the top 100 are mainly from the Automobiles & Parts (8), 
Pharmaceuticals & Biotechnology (7) and ICT sectors (5). The US companies are mainly from 
the ICT (13), Pharmaceuticals & Biotechnology (10), and Chemicals (3) sectors. The Japanese 
companies operate mainly in the Automobiles & Parts (5), ICT (4) and Pharmaceuticals (4) 
sectors. 
Seventy-one companies in the top 100 have shown positive R&D investment growth. Among 
them, 30 companies had double-digit R&D growth, and of these, 17 companies also showed 
double-digit growth in net sales.   
Most of the top 100 companies showing the largest R&D increases are in the Automobiles & 
Parts sector, e.g. Tata Motors, India (77.6%);  Fiat, Italy (51.5%); Volkswagen, Germany 
(32.1%); BMW, Germany (17.2%), Bosch, Germany (16.1%) and in ICT sectors, e.g. 3M, US 
(57.7%); Western Digital, US (49.0%); Apple, US (39.2%); Qualcomm, US (30.7%), Huawei, 
China (30.3%), Google, US (27.7%). 
Other companies among the top 100 group have shown double-digit growth in both R&D 
and net sales, e.g. Gilead Sciences and EBay from the US; SAP from Germany; Novo Nordisk 
from Denmark; Samsung Electronics from South Korea.    
Twenty-eight companies in the top 100 have experienced a decrease in R&D investing. 
Among these, three companies decreased R&D investments and net sales by more than 
10 %:  Renesas, Japan; Nokia, Finland and Vale, Brazil. 
The R&D intensity of companies in the top 100 (6.4%) has increased slightly due to a higher 
rate of increase for R&D (6.2 %) than for net sales (5.7 %). The EU companies in the top 100 
have a higher average R&D intensity (6.9 %) than that of non-EU companies (6.2 %).  
                                                       
10 This year, the figures of VOLKSWAGEN include those of its new subsidiary PORSCHE that in 2011 reported €1046 of R&D investment. This amount of 
R&D accounts approximately for 50 % of the VOLKSWAGEN's increase of R&D in 2012.     
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R&D changes driven by Mergers and Acquisitions (M&As) 
 
The growth in R&D investment may either be organic or driven by M&As, or it may be a 
combination of the two. M&As (or demergers) may take place within or between 
regions/sectors and can significantly impact the ranking of companies in the Scoreboard. 
While acquisitions are not systematically captured in this report, some examples that had a 
significant effect on companies in the top positions are provided in table 2.1 below.    
 
Table 2.1.  Merger and acquisition activity involving Scoreboard companies  
Acquiror
Deal value
€m Target name Vendor
Completed 
date Deal type
JOHNSON & JOHNSON 14353.2 SYNTHES INC. SHAREHOLDERS 14/06/2012 Acq. 100%
GOOGLE  9758.0 MOTOROLA MOBILITY  SHAREHOLDERS 22/05/2012 Acq. 100%
NESTLÉ SA 9125.7 PFIZER INC.'S INFANT 
NUTRITION 
PFIZER INC. 30/11/2012 Acq. 100%
MICROSOFT  6164.2 SKYPE GLOBAL SARL SILVER LAKE PARTNERS  13/10/2011 Acq. 100%
BRISTOL-MYERS SQUIBB 5647.6 AMYLIN 
PHARMACEUTICALS INC.
SHAREHOLDERS 08/08/2012 Acq. 100%
VOLKSWAGEN 4490.0 PORSCHE  AG PORSCHE  AUTOMOBIL  01/08/2012 Acq.  from 49.9% to 100%
CISCO SYSTEMS  4070.5 NDS GROUP LTD NEWS CORPORATION 31/07/2012 Acq. 100%
GENERAL ELECTRIC  3234.6 AVIO SPA'S AVIATION  BCV INVESTMENTS SCA 01/08/2013 Acq. 100%
GENERAL ELECTRIC  2535.9 LUFKIN INDUSTRIES INC. 01/07/2013 Acq. 100%
GLAXOSMITHKLINE 2463.7 HUMAN  GENOME 
SCIENCES INC.
TAUBE HODSON 
STONEX PARTNERS
03/08/2012 Acq. 100% - Bid 2 -  offer
VOLKSWAGEN 2083.4 MAN AG 09/11/2011 Acq.  from 30.47% to 53.71%
SIEMENS  2057.9 INVENSYS RAIL GROUP INVENSYS PLC 02/05/2013 Acq. 100%
BRISTOL-MYERS SQUIBB  1888.5 INHIBITEX INC. 13/02/2012 Acq. 100%
NOKIA 1700.0 NOKIA SIEMENS  SIEMENS  07/08/2013 Acq.  from 50% to 100%
IBM 1559.0 SOFTLAYER GLOBAL  INNOVATION  08/07/2013 Acq. 100%
ORACLE 1452.7 TALEO  CORPORATION 11/04/2012 Acq. 100%
ORACLE 1151.0 RIGHTNOW  25/01/2012 Acq. 100%
DENSO 1136.0 RENESAS  ELECTRONICS  30/09/2013 Acq. 74.979%
TOSHIBA  1096.2 WESTINGHOUSE ELECTRIC  NUCLEAR ENERGY  04/01/2013 Acq.  from 67% to 87%
SONY 1063.1 M3  INC. SO-NET  11/01/2013 Acq. 55.8%
SONY 1050.0 SONY  ERICSSON  MOBILE  TELEFONAKTIEBOLET  31/01/2012 Acq.  from 50% to 100%
 ERICSSON 904.9 TELCORDIA  WARBURG PINCUS LLC 12/01/2012 Acq. 100%
GOOGLE 777.0 WAZE  INC. KLEINER  PERKINS  11/06/2013 Acq. 100%
DAIMLER  767.0 BEIJING FOTON DAIMLER  18/02/2012 Joint venture 100%
SONY 535.5 SO-NET  ENTERTAINMENT  20/09/2012 Acq.  from 57.974% to 95.609% 
HUAWEI 398.4 HUAWEI  SYMANTEC  SYMANTEC  30/03/2012 Acq.  from 51% to 100%
IBM 275.9 ALGORITHMICS INC. FITCH INC. 21/10/2011 Acq. 100%
AMGEN  251.6 KAI PHARMACEUTICALS  THOMAS WEISEL  05/07/2012 Acq. 100%
GLAXOSMITHKLINE  250.0 OKAIROS AG NOVARTIS VENTURE  29/05/2013 Acq. 100%
SAMSUNG ELECTRONICS  239.9 CSR PLC'S DEVELOPMENT  CSR PLC 04/10/2012 Acq. 100%
VOLKSWAGEN 139.5 MAN SE 05/06/2012 Acq.  from 73.76% to 75.03%
INTEL  105.8 CRAY INC.'S HIGH- CRAY INC. 02/05/2012 Acq. 100%
  Source : Zephir database by Bureau van Dijk. 
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Long-term performance of top R&D companies 
 
This section analyses the behaviour of the top companies over the last 10 years based 
on our history database containing company data for the period 2002-2012.  Results of 
companies showing outstanding R&D and economic results are underlined.  
 
Ranking of the top 50 
Table 2.2 shows the evolution of the R&D rankings of the top 50 companies since the 
first  Scoreboard in 2004 and the most important changes are highlighted. It is 
important to note, as stated in the previous section and in past reports, that the 
growth of companies is often accompanied by mergers and acquisitions.  
There are 16 EU companies (18 in 2004) and 34 non-EU companies (32 in 2004). In the 
EU group, three companies left the top 50 (Philips, Renault and BAE Systems) and one 
company joined the top 50 (Boehringer Ingelheim). In the non-EU group, eight 
companies left the top 50 (Fujitsu, Matsushita Electric, NEC, Motorola, Nortel 
Networks, Wyeth, Delphi, Sun Microsystems) and ten companies joined the top 50 
(Abbott, Amgen, Apple, Denso, Google, Huawei, Oracle, Panasonic, Qualcomm and 
Takeda Pharmaceuticals). 
The distribution of the top 50 companies by main industrial sector and region changed 
from 2004 to 2012 as follows: 
•  Automobiles & Parts, from 13 (EU 7) to 12 (EU 6) 
•  ICT industries,   from 13 (EU 3) to 14 (EU 3) 
•  Pharma & Biotech,  from 11 (EU 3) to 15 (EU 5) 
The EU companies that improved by at least 10 places are Boehringer Ingelheim (now 
ranked 41
st) and Sanofi (now 15
th). The latter was created after 2004 and is an example 
of R&D growth driven by M&As.  
There are 15 non-EU companies that gained more than 10 places. They include Google, 
up more than 200 (now 13
th), Panasonic, up 128 (now 19
th), Qualcomm, up 87 (now 
37
th), Huawei, up more than 200 (now 31
st), Oracle, up 40 (now 29
th).  
Companies which dropped ten or more places but remained within the top 50 include 
Siemens (now 17
th), IBM (now 21
st), Ford Motor (now 23
rd), Ericsson (now 28
th), NTT 
(now 49
th), Hewlett-Packard (now 44
th), and Nokia (now 22
nd).  
 
Best performers among the top 100 
Among the top 100 group, 14 companies have simultaneously increased R&D and net 
sales by more than 200% since 2004 while showing positive operating profits in the last 
reporting period. Nine of these companies are based in the US, two in China and one 
each in Taiwan, India and Brazil (see table 2.3).  
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Figure 2.1.  The world's top 50 companies by their total R&D investment (€m) in the 2013 Scoreboard. 
0 1 000 2 000 3 000 4 000 5 000 6 000 7 000 8 000 9 000 10 000
50. NTT, Japan
49. ALCATEL-LUCENT, France
48. PEUGEOT (PSA), France
47. AMGEN, USA
46. APPLE, USA
45. HEWLETT-PACKARD, USA
44. CANON, Japan
43. TOSHIBA, Japan
42. BOEHRINGER INGELHEIM, Germany
41. TAKEDA PHARMACEUTICAL, Japan
40. BRISTOL-MYERS SQUIBB, USA
39. DENSO, Japan
38. QUALCOMM, USA
37. HITACHI, Japan
36. BAYER, Germany
35. ABBOTT LABORATORIES, USA
34. FIAT, Italy
33. ASTRAZENECA, UK
32. GENERAL ELECTRIC, USA
31. HUAWEI, China
30. EADS, The Netherlands
29. ORACLE, USA
28. ERICSSON, Sweden
27. BMW, Germany
26. ELI LILLY, USA
25. NISSAN MOTOR, Japan
24. SONY, Japan
23. FORD MOTOR, USA
22. NOKIA, Finland
21. IBM, USA
20. GLAXOSMITHKLINE, UK
19. PANASONIC, Japan
18. CISCO SYSTEMS, USA
17. SIEMENS, Germany
16. HONDA MOTOR, Japan
15. SANOFI-AVENTIS, France
14. ROBERT BOSCH, Germany
13. GOOGLE, USA
12. GENERAL MOTORS, USA
11. DAIMLER, Germany
10. PFIZER, USA
9. JOHNSON & JOHNSON, USA
8. MERCK US, USA
7. NOVARTIS, Switzerland
6. ROCHE, Switzerland
5. TOYOTA MOTOR, Japan
4. INTEL, USA
3. MICROSOFT, USA
2. SAMSUNG ELECTRONICS, South Korea
1. VOLKSWAGEN, Germany
R&D investment (Euro million)
USA
EU
Japan
South Korea
Switzerland
China
 
                 
Source:   The 2013 EU Industrial R&D Investment Scoreboard.       European Commission, JRC/DG RTD.  
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Rank in 2012 Company Rank change 2004-2012
1V O L K S W A G E N up 7
2 SAMSUNG ELECTRONICS up 31
3 MICROSOFT up 10
4I N T E L up 10
5 TOYOTA MOTOR dow n 1
6R O C H E up 11
7N O V A R T I S up 13
8M E R C K  U S up 21
9J O H N S O N  &  J O H N S O N up 3
10 PFIZER dow n 8
11 DAIMLER dow n 8
12 GENERAL MOTORS dow n 6
13 GOOGLE up > 200 
14 ROBERT BOSCH up 12
15 SANOFI up 40
16 HONDA MOTOR nil
17 SIEMENS down 13
18 CISCO SYSTEMS up 13
19 PANASONIC up 128
20 GLAXOSMITHKLINE dow n 9
21 IBM down 12
22 NOKIA down 12
23 FORD MOTOR down 22
24 SONY dow n 9
25 NISSAN MOTOR up 9
26 ELI LILLY up 15
27 BMW up 1
28 ERICSSON down 11
29 ORACLE up 42
30 EADS up 5
31 HUAWEI up > 200 
32 GENERAL ELECTRIC up 5
33 ASTRAZENECA dow n 8
34 FIAT up 10
35 ABBOT LABORATORIES up 17
36 BAYER dow n 4
37 HITACHI down 13
38 QUALCOMM up 99
39 DENSO up 13
40 BRISTOL-MYERS SQUIBB up 2
41 TAKEDA PHARMACEUTICAL up 31
42 BOEHRINGER INGELHEIM up 20
43 TOSHIBA down 13
44 CANON dow n 5
45 HEWLETT-PACKARD down 22
46 APPLE up 109
47 AMGEN up 9
48 PEUGEOT (PSA) down 10
49 ALCATEL-LUCENT down 32
50 NTT down 29
Table 2.2  R&D ranking of the top 50 companies in the 2004 and 2013 Scoreboards. 
Note : Companies in "blue" went up more than 20 ranks and companies in "red" lost more than 20 ranks.
Source:   The EU Industrial R&D Investment Scoreboards 2013 and 2004.    
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Table 2.3.  Ranking of companies among the top 100 R&D investors that achieved the   
best performance over the last 10 years*.   
 
rank 
 
Company  Country
 
 
Sector 
 
R&D in 2012 
(€ m) 
1  GOOGLE USA  Internet  4997.0 
2  ORACLE USA  Software  3675.9 
3  QUALCOMM USA  Telecommunications Equipment  2967.3 
4  APPLE USA  Computer  Hardware  2562.5 
5  BROADCOM USA  Semiconductors  1756.9 
6  PETROCHINA  China  Oil & Gas Producers  1741.6 
7  TATA MOTORS  India  Automobiles & Parts  1496.0 
8  EBAY USA  General  Retailers  1408.2 
9  GILEAD SCIENCES  USA  Biotechnology  1333.9 
10  CELGENE USA  Biotechnology  1205.8 
11  HON HAI 
PRECISION IND.  Taiwan Electronic  Equipment  1191.6 
12  WESTERN 
DIGITAL USA  Computer  Hardware  1191.5 
13  ZTE China  Telecommunications  Equipment  1170.5 
14  VALE Brazil  Mining  1120.2 
* These companies increased simultaneously R&D investment and net sales by more than 200 % from 2004 to 
2012 and had positive operating profits in 2012. 
Source:   The 2013 EU Industrial R&D Investment Scoreboard. 
                European Commission, JRC/DG RTD.  
 
38  The 2013 EU Industrial R&D Scoreboard
   
 
The 2013 EU Industrial R&D Investment Scoreboard 39
 
3.  R&D distribution by industrial sector 
 
 
This chapter presents the main R&D trends among Scoreboard companies aggregated 
by industrial sectors
11. It comprises the ranking of sectors by their level of R&D 
investment, R&D intensities, rates of R&D growth and the comparison of such trends 
across world regions.  
 
 
 
Key findings 
•  Companies from three out of the top five sectors by level of R&D investment 
increased R&D above the world average of 6.2%, namely Software & Computer 
Services (11.7%), Automobiles & Parts (8.9%) and Technology Hardware & 
Equipment (8.8%). The top R&D investing sector, Pharmaceuticals and 
Biotechnology achieved a more modest 4.1% increase of R&D. Other sectors that 
showed high R&D growth were the Industrial Engineering (9.8%) and Health Care 
Equipment & Services (8.3%) sectors. 
•  Companies based in the EU had the highest R&D growth in Automobile & Parts 
(14.4%), Software & Computer Services (14.2%) and the Industrial Engineering 
(12.3%) sectors.  
•  Trends observed in the Scoreboard over the last 10 years show a characteristic 
sector specialisation by region. The largest R&D shares of the companies based in 
the EU are in Automobiles & Parts (24.9%), Pharmaceuticals & Biotechnology 
(17.5%) and Technology Hardware & Equipment (10.2%). The main R&D shares of 
those based in the US specialise in high R&D-intensive sectors, namely Technology 
Hardware & Equipment (25.2%), Pharmaceuticals & Biotechnology (22.1%) and 
Software & Computer Services (18.2%). These three high R&D-intensity sectors 
account for 65.5% of US R&D, 30% for the EU and 26% for Japan. 
 
 
General R&D trends 
Figure 3.1 shows the R&D rankings of companies from the main industrial sectors 
including the relative R&D share by main world region. The specialisation of the main 
world regions, represented by the share of sectors within the regions' total R&D 
investment, is given in figure 3.2. 
•  R&D investment in the Scoreboard remains highly concentrated by sectors: Out of 
40 industrial sectors, the top three –Pharmaceuticals & Biotechnology, Technology 
Hardware & Equipment and Automobiles & Parts– account for 50.2% of the total 
R&D investment by the Scoreboard companies; the top 6 and top 15 sectors 
constitute, respectively, 71.0% and 92.1% of the total R&D in the Scoreboard. A 
similar concentration of R&D by industrial sector has been observed over the last 
10 years. 
                                                       
11 According to the Industry Classification Benchmark (ICB) applied in the Scoreboard.  
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•  The ranking of the top 15 sectors has changed as follows: The Industrial 
Engineering sector took over the 6
th position from the Chemicals sector (now 7
th), 
the General Industrials sector took the 9
th position from the Leisure Goods (now 
10
th). 
•  The Pharmaceuticals & Biotechnology sector keeps the first position in the R&D 
ranking, slightly increasing its R&D share of the total R&D investment which is now 
18.1%. It is followed by the Technology Hardware & Equipment sector with a share 
of 16.4% (similar to last year's 16.6%) and the Automobile & Parts sector with 
15.7%, slightly higher than the 15.0% of last year. 
•  The R&D specialisation (share of R&D investment) of the main regions in the top 3 
sectors are:  
In the EU, Automobiles & Parts (24.9%), Pharmaceuticals & Biotechnology (17.5%), 
and Technology Hardware & Equipment (10.2%);  
In the US, Technology Hardware & Equipment (25.2%), Pharmaceuticals & 
Biotechnology (22.1%) and Automobiles & Parts (6.6%); 
 In Japan, Automobiles & Parts (26.4%), Pharmaceuticals & Biotechnology (10.8%) 
and Technology Hardware & Equipment (7.3%). 
• The contribution to the total Scoreboard R&D by EU companies is 53.0% to 
Aerospace & Defence, 46.1% to Automobiles & Parts and 39.5% to the Industrial 
Engineering sectors; the US contributes 74.4% to Software and Computer Services, 
63.8% to Health Care Equipment & Services and 54.0% to Technology Hardware & 
Equipment and; Japan contributes 34.5% to Chemicals, 33.3% to the Electronic & 
Electric Equipment sector and 31.8% to Automobiles & Parts. 
 
  
R&D growth by industrial sector 
The actual contribution of an industrial sector to the overall R&D growth of a region 
depends on its rate of R&D change and the sector's share of total R&D of the region. 
Figures 3.1 and 3.2 show the shares of the main industrial sectors and table 3.1 
shows their ranking by R&D annual growth rate worldwide for the Scoreboard 
companies based in the main world regions (EU-527, US-658, and Japan-353). 
The following points are observed for the top 15 sectors accounting for 92.1% of the 
total R&D investment of the Scoreboard companies: 
 
•  Worldwide, the Software & Computer Services sector shows the highest one-year 
growth rate (11.8%), followed by Industrial Engineering (9.8%), Automobiles & 
Parts (8.9%) and Technology Hardware & Equipment (8.8%) sectors. 
•  Among the companies based in the EU, the Automobiles & Parts sector shows the 
highest one-year growth rate (14.4 %), followed by the Software & Computer 
Services (14.2 %) and Industrial Engineering (12.3 %) sectors. Sectors showing the 
lowest one-year R&D growth are Banks (for which only the EU companies report 
R&D, -6.8 %), Fixed Line Telecom (-4.6%), and Technology Hardware & Equipment 
(-2.3 %).   
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•  Among the companies based in the US, the Technology Hardware & Equipment 
sector shows the highest one-year growth rate (14.8 %) followed by Software & 
Computer Services (12.6 %) and Industrial Engineering (9.4%). Sectors showing the 
lowest one-year R&D growth are Food Producers (-12.4 %) and Leisure Goods (-4.6 
%).  
•  For Japanese companies, the highest one-year growth rate is shown by 
Automobiles & Parts (6.4 %) and Health Care Equipment & Services (4.9 %). The 
poorest performance was shown by General Industrials (-9.7 %) and Electronic & 
Electrical Equipment (-6.9 %). 
 
Apart from the top 15 industries, there were important R&D changes in some other 
sectors: 
•  The alternative energy sub-sector that has shown a substantial increase of R&D 
investment over the past years sharply reduced R&D in 2012 (-26.1 %). 
•  Other sectors showing considerable R&D growth are Food & Drug Retailers (48.0 
%) and Industrial Transportation (30.3%). 
 
 
 
 
 
 
Figure 3.1. R&D ranking of industrial sectors and share of main world regions for the 
world's top 2000 companies. 
 
20 40 60 80 100
Pharmaceuticals & Biotechnology
Technology Hardware &…
Automobiles & Parts
Software & Computer Services
Electronic & Electrical Equipment
Industrial Engineering
Chemicals
Aerospace & Defence
General Industrials
Leisure Goods
Health Care Equipment & Services
Oil & Gas Producers
Fixed Line Telecommunications
Banks
Food Producers
R&D investment 2012 (€ bn)
EU
USA
Japan
other countries
Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD.  
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Figure 3.2.       R&D shares of sectors of the main world regions 
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Table 3.1.  Ranking of top 15 industrial sectors by overall one-year R&D growth for the EU, 
US and Japanese companies in the 2013 Scoreboard. 
Rank  Sector 
Overall 
one-
year 
R&D 
growth 
(%) 
EU-527  
 
R&D change (%) 
 
1 year       3 years      
US-658 
 
R&D change 
(%) 
 
1 year    3 years   
Japan-353  
 
R&D change (%) 
 
1 year      3 years   
1 
Software & Computer 
Services  11.8 14.2 10.0  12.6  10.4  -4.7 -8.4 
2  Industrial Engineering  9.8  12.3  10.0  9.4  13.3  3.4  4.2 
3  Automobiles & Parts  8.9  14.4  12.6  -2.6  5.1  6.4  5.3 
4 
Technology Hardware 
& Equipment  8.8 -2.3 1.4  14.8  9.7  -4.1  -0.5 
5 
Health Care Equipment 
& Services  8.3 8.7 7.6  8.5  6.2  4.9  3.9 
6  Aerospace & Defence  7.0  9.5  6.1  -1.3  1.3       
7  Chemicals  6.9 8.6 3.8  7.0  8.4  0.7  0.9 
8 
Pharmaceuticals & 
Biotechnology  4.1 3.2 3.7  4.3  5.7  4.8  -0.1 
9  Oil & Gas Producers  3.8  9.5  4.7  2.2  1.4  -4.9  9.8 
10  Leisure  Goods  2.9 1.7 2.5  -4.6  -2.6  2.5  2.2 
11 
Electronic & Electrical 
Equipment  2.5 4.4 4.2  6.1  8.2  -6.9  0.6 
12  Food  Producers  1.1 6.3 7.2  -12.4  1.8  0.0  1.6 
13 
Fixed Line 
Telecommunications  0.6 -4.6 -6.1  7.5  9.3  0.5  -1.1 
14  General  Industrials  0.2 5.6 4.7  7.2  10.2  -9.7  -3.2 
15  Banks  -4.3  -6.8  13.4             
  Total 40 industries  6.2 6.3 6.6  8.2  8.0  0.4  1.2 
Source:   The 2013 EU Industrial R&D Investment Scoreboard. 
               European Commission, JRC/DG RTD  
 
44  The 2013 EU Industrial R&D Scoreboard
 
R&D intensity by sector 
Table 3.2 provides the list of industrial sectors ranked by worldwide R&D intensity of 
the main industrial sectors for the 2000 Scoreboard companies grouped by main 
world region.  
 
The following points are observed: 
 
•  Some industrial sectors increased their R&D intensity as R&D investment 
increased more than net sales in 2012, in particular the Technology Hardware & 
Equipment (8.8% vs. 1.9%) and the Industrial Engineering sector (9.8% vs. 3.5%). 
The opposite happened for the Electronic & Electric Equipment sector (2.4% vs 
5.5%).  
•  Four sectors have an R&D intensity of more than 5.0%: Pharmaceuticals & 
Biotechnology, IT sectors (Software & Computer Services and Technology 
Hardware & Equipment) and Leisure Goods. The sector with the lowest R&D 
intensity is Oil & Gas Producers (0.3%).  
•  Among the top 15 sectors, the R&D intensity of EU companies is larger than that 
of the US and Japan in 6 sectors (Software & Computer Services, Technology 
Hardware & Equipment, Industrial Engineering, General Industrials and 
Automobiles & Parts and Aerospace & Defence) but the EU sector is much smaller 
than that of the US one for the first two of these sectors. Japanese companies 
show higher R&D intensity than the EU and the US in sectors such as Electronic & 
Electrical Equipment and Chemicals. The R&D intensity of US companies is higher 
than that of the EU and Japan in Pharmaceuticals & Biotechnology. 
•  As observed in previous Scoreboards, the overall lower average of R&D intensity of 
the EU companies is due to their large share of low R&D-intensive sectors as 
compared to a similar group of non-EU companies. Conversely, the high average  
R&D intensity of the US companies is due to their considerable weight in high 
R&D-intensive sectors (see Figures 3.1 and 3.2) 
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Table 3.2.   Ranking of industrial sectors by overall R&D intensity for the EU, US and     
Japanese companies in the 2013 Scoreboard. 
Rank  Sector 
Overall 
sector R&D 
intensity, % 
EU-527  
sector R&D 
intensity, % 
US-658 
sector R&D 
intensity, % 
Japan-353  
sector R&D 
intensity, % 
1 
Pharmaceuticals & 
Biotechnology  14.4  13.9  15.8  13.2 
2 
Software & Computer 
Services  9.9  12.6  11.5  4.8 
3 
Technology Hardware & 
Equipment  7.9  14.5  8.8  6.1 
4  Leisure Goods  6.3  3.3  5.3  6.7 
5  Aerospace & Defence  4.5  6.0  3.0    
6 
Electronic & Electrical 
Equipment  4.3  4.8  4.3  5.2 
7  Automobiles & Parts  4.2  5.1  3.7  4.3 
8 
Health Care Equipment & 
Services  4.1  3.6  3.9  6.9 
9  Industrial Engineering  2.8  3.5  3.0  2.0 
10  Chemicals  2.7  2.0  3.4  3.9 
11  General Industrials  2.5  5.1  3.1  2.2 
12  Banks  2.0  1.8       
13 
Fixed Line 
Telecommunications  1.7  1.5  1.1  2.5 
14  Food Producers  1.3  1.5  0.9  1.5 
15  Oil & Gas Producers  0.3  0.3  0.3  0.2 
   Total 40 industries  3.2  2.6  4.9  3.5 
Source:   The 2013 EU Industrial R&D Investment Scoreboard. 
               European Commission, JRC/DG RTD  
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Growth of net sales and profitability by industrial sector 
 
Table 3.3 shows the ranking of the top 15 industrial sectors by overall one-year 
growth of net sales for the companies based in the EU, the US and Japan. It also 
includes the sector profitability for these regions. 
The following points are observed: 
•  Worldwide, the Automobiles & Parts sector shows the highest one-year growth 
rate of net sales (8.8%), followed by Software & Computer Services (7.4%), Food 
Producers (7.3%) and Aerospace & Defence (6.4%). Regarding the automotive 
sales, it is worth noting a couple of points: First, the Japanese earthquake in 2011 
meant that sales recovered strongly in 2012 as Toyota and others ramped 
production back up. Second, 2012 vehicle sales in units were up 5.2% but volume 
fell 5.9% in Europe with only Russia and the UK showing reasonable increases 
(figures from wardsauto.com). This means that the Scoreboard sales growth 
figures for European automotive companies suggest that they did well in exporting 
to the expanding markets of North America and Asia Pacific. 
•  Among the companies based in the EU, the highest growth rates of net sales are in 
Leisure Goods (16.3%), the Automobiles & Parts sector (11.3%) and Food 
Producers (10.1%). The sector showing the lowest one-year sales growth is 
Technology Hardware & Equipment (-9.3%). Among the largest sectors in the EU, 
the highest profitability is shown in Pharmaceuticals & Biotechnology (19.0%) and 
Software & Computer Services (18.2%). The EU companies’ negative profitability 
of the Technology Hardware & Equipment sector (-1.1%) is mostly due to large 
losses incurred by Nokia, STMicroelectronics and Alcatel-Lucent.  
•  Among the companies based in the US, the Software & Computer Services sector 
shows the highest one-year growth rate for sales (6.9%) followed by Technology 
Hardware & Equipment (6.8%). Sectors showing the lowest one-year R&D growth 
are Leisure Goods (-2.7%) and Oil & Gas Producers (-3.0%). The US-based 
companies have the highest profitability in Software & Computer Services (23.9%) 
and Pharmaceuticals & Biotechnology (21.7%). The US companies’ negative 
profitability of the Automobiles & Parts sector (-3.2%) to a large extent reflects the 
major losses of General Motors. The negative sales growth rate in Pharmaceuticals 
& Biotechnology (-0.3%) reflects patent expiries for Pfizer, BMS and Abbott. 
•  For Japanese companies, the highest one-year growth rate is shown by 
Automobiles & Parts (11.9%) and Pharmaceuticals & Biotechnology (3.5%). The 
poorest performance is shown by the Health Care Equipment & Services sector (-
1.7%). The profitability of companies based in Japan is generally lower than their 
counterparts in the EU and the US, for example 8.9% in Pharmaceuticals & 
Biotechnology vs. 19.0% for the EU companies.  
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Table 3.3.  Ranking of top 15 industrial sectors by overall one-year sales growth for the EU, US 
and Japanese companies in the 2013 Scoreboard. 
    World-
wide 
 
EU-527 
 
US-658 
 
Japan-353  
 
Rank 
Sector 
 
 
Sales 
growth 
1y (%) 
Sales 
growth 
1y (%)  Profit.* 
Sales 
growth 
1y (%)  Profit.* 
Sales 
growth 
1y (%) 
Profit.
* 
1  Automobiles & Parts  8.8  11.3  5.2  0.0  -3.2  11.9  5.6 
2 
Software & Computer 
Services 7.4  9.7  18.2  6.9  23.9  -0.2  2.8 
3  Food Producers  7.3  10.1  10.7  3.8  10.4  1.6  3.5 
4  Aerospace & Defence  6.4  8.3  7.0  6.7  9.0       
5 
Electronic & Electrical 
Equipment  5.5 5.0 9.1 1.2  13.1  -1.3  3.2 
6  Oil & Gas Producers  3.7  2.8  9.4  -3.0  16.7  2.3  1.8 
7 
Health Care Equipment 
& Services  3.5 8.7  15.4 2.1  8.5  -1.7  7.6 
8  Industrial Engineering  3.5  4.1  8.4  6.4  11.6  2.6  5.0 
9  Chemicals 2.2  3.0  9.9  3.7  10.8  -1.5  4.4 
10 
Technology Hardware 
& Equipment  1.9 -9.3 -1.1 6.8  14.9  -1.2  6.6 
11 
Pharmaceuticals & 
Biotechnology  1.9 2.8  19.0  -0.3  21.7  3.5  8.9 
12  General Industrials  1.5  6.9  6.4  4.7  11.6  -0.2  4.2 
13 
Fixed Line 
Telecommunications  0.5 -1.1 8.7  0.7  10.1  1.8  11.5 
14  Banks  -1.1  -1.8  6.8             
15  Leisure Goods  -1.4  16.3  21.0  -2.7  9.1  -0.5  3.6 
   Total 40 industries  4.2 4.3 8.1 2.9  13.0  3.3  4.4 
* Profitability:  operating profits as percentage of net sales. 
 
Source:   The 2013 EU Industrial R&D Investment Scoreboard. 
               European Commission, JRC/DG RTD  
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Changes in indicators by region and sector groups 
 
It is interesting to see the distribution of R&D investment of the Scoreboard 
companies across regions and sectors using an aggregation of the 40 industrial 
sectors into four groups of high-, medium-high-, medium-low- and low- R&D intensity 
(see Box 1.1 in chapter 1). 
The worldwide and domestic distribution of the R&D investment by the 2000 
Scoreboard companies shows clear differences by world region, illustrating 
respectively the weight of the region in the world and its specialisation (See Table 
3.4):  
•  Companies based in the EU specialise in medium-high R&D-intensive sectors 
(44.5% of total R&D of the EU companies) and contribute 34.8% of the total world 
R&D of that sector group. Two sectors, Automobiles & Parts and Industrial 
Engineering, account for almost 70% of the total R&D investment of the EU's 
medium-high R&D intensity group. 
•  Those based in the US specialise in high R&D intensive sectors (73.3% of total R&D 
of the US companies) and contribute 50.3 % of the world R&D of that sector 
group. Three sectors, Pharmaceuticals & Biotechnology, Technology Hardware & 
Equipment and Software & Computer Services, account for almost 90% of the 
total R&D investment of the US's high R&D intensity group. 
•  Japanese companies specialise in medium-high R&D intensive sectors (58.2%) 
while contributing 29.4% of world R&D of that sector group. Two sectors, 
Automobiles & Parts and Electronics & Electric Equipment, account for 68.6% of 
Japan's medium-high R&D intensity group. 
 
Table 3.4.   World and domestic R&D distribution of the 2000 Scoreboard companies by 
sector groups for the main regions. 
 Sector  
 
High  Medium-high  Medium-low  Low    
                 
   Share, %   Share, %  Share, %  Share, %  Total 
Region                
  world         domestic    world          domestic      world        domestic         world      domestic     domestic     
 
EU  22.3 39.0 34.8 44.5 40.4 6.4 45.1 10.1 100
 
US  50.3 73.3 20.7 22.1 25.2 3.3 7.0  1.3 100
 
Japan  12.2 33.0 29.4 58.2 19.8 4.9 11.4  3.9 100
Other 
countries  15.2 47.0 15.2 34.4 14.7 4.1 36.5 14.5 100
Total 
world  100   100  100   100       
Note : Sector groups as defined in Box 4.1. 
  
Source:   The 2013 EU Industrial R&D Investment Scoreboard. 
               European Commission, JRC/DG RTD   
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4.  The top 1000 R&D investors in the EU 
 
This chapter discusses the R&D and economic trends of companies based in 
Members States of the EU. This specific analysis is based on an extended sample of 
companies representing the top 1000 R&D investors in the EU, i.e. the 527 EU 
companies included in the world top 2000 sample and 473 additional companies 
based in the EU.  The main questions addressed are firstly about the one-year 
changes in R&D and economic indicators of companies based in the top 10 Member 
States by level of R&D investment. The second question regards the long-term trends 
of company results, namely the rate of growth of R&D and net sales and profitability 
for companies based in the top three Member States of the EU.  
 
Key findings 
•  Companies based in Germany, the top R&D investor, continued with the good 
performance shown in the past year, increasing R&D in 2012 to well above the 
world average, at 11.6 %. On the contrary, companies based in the UK and France 
showed a poor performance, increasing R&D by 0.5% and 2.3% respectively.       
•  Among the group of the 10 largest EU countries, those whose companies 
increased R&D above the EU average were Italy (18.3 %), Ireland (10.7 %), the 
Netherlands (7.7 %) and Sweden (6.7 %). Companies based in three countries 
decreased R&D in 2012: Finland (-10.3 %), Denmark (-3.0 %) and Spain (-2.1 %). 
These three countries have their total R&D dominated by that of only a few 
companies, e.g. Nokia accounting for nearly 74% of Finland's R&D in the 
Scoreboard. 
•  The analysis of 10-year trends of R&D and economic results for companies based 
in Germany, the UK and France show the effects of the crisis in 2008-2009 and the 
strong recovery over 2010-2012 for the German companies. 
 
Overview of the EU 1000 companies   
The composition of the sample of the EU 1000 companies across industrial sectors 
and countries is found in Annex 3.  This sample, as well as the global 2000, shows a 
high concentration of companies by sector and country. The 6 largest sectors in 
terms of R&D account for 50% of the companies. These sectors and the countries 
accounting for at least 15% of the companies each are: 
 
•  Software & Computer Services   113 :  UK 47, France 21, Germany 19 
•  Pharmaceuticals & Biotechnology  112 :  UK 30,  France 18 
•  Industrial Engineering   112 :  Germany 42 
•  Electronic & Electrical Equipment  73 :  Germany 16, UK 15, France 12 
•  Automobiles & Parts   50 :  Germany 20, UK 11, France 6 
•  Technology Hardware & 
Equipment   46 :  UK 11, Germany 7, Sweden 7 
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A look at the lower reaches of the EU top 1000 companies 
 
Table 4.1 below compares the sector composition of the upper (EU companies which 
belong to the World top 2000 companies) and lower reaches of the top 1000 EU 
Scoreboard companies across the 6 largest sectors in terms of R&D investments. 
 
 
Table 4.1 Distribution of top and bottom EU companies in selected sectors 
 
Selected sectors 
 
Top group of EU 1000 
(number of firms) 
Bottom group of EU 
1000 (number of firms) 
Pharmaceuticals & 
Biotechnology  59 (23%)  52 (21%) 
Software & Computer 
Services  37 (14%)  74 (30%) 
Technology Hardware & 
Equipment  29 (11%)  17 (7%) 
Electronic & Electrical 
Equipment  38 (15%)  38 (16%) 
Automobiles & Parts  36 (14%)  14 (6%) 
Industrial Engineering  62 (24%)  50 (20%) 
Total 261  245 
 
Source:   The 2013 EU Industrial R&D Investment Scoreboard. 
   European Commission, JRC/DG RTD. 
 
 
A closer look at the lower reaches of the EU Scoreboard companies (i.e. EU top 1000 
companies which do not belong to the World top 2000 companies) provides 
interesting insights regarding future potential leading EU companies. The general 
picture reveals that: 
•  More than 55% of these companies in the sectors of Electronic and Electrical 
Equipment, Pharmaceuticals & Biotechnologies and Software & Computer services 
have a higher R&D intensity than the average of the 527 EU companies.  
•  The share of companies with a higher R&D intensity than that of the top European 
companies exceeds 40% in the sectors of Industrial Engineering and Technology 
Hardware & Equipment.  
•  This proportion drops to about 20% in the sector of Automobiles & Parts since 
almost all the vehicle manufacturers are in the top 527.  
 
The country distribution of the lower reach reveals that four countries account for 
about 75% of the total number of companies within the six selected sectors. The UK 
and Germany represent respectively 30% and 20% of the companies in these sectors 
while the proportions are about 15% and 10% for France and Sweden. Figure 4.1 
below gives a more detailed view of the distribution of companies in the lower and 
upper reaches of the top 1000 EU for these four countries.   
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  Co   in the top 10 EU Member States 
 
With respect to the sector distribution of R&D intensity by country, the following main 
points are observed:  
•  In the Automobile and Parts sector, only UK companies display a higher R&D 
intensity than that of the average of the top 527 EU companies.  
•  All the Swedish companies operating in the Technology Hardware and 
Equipment sector show higher performances, as compared to the upper reach 
average.  
•  In the sector of Electronic and Electrical Equipment, French and German 
companies record a higher R&D intensity than the average of the top 527 EU 
companies. 
•  In the Industrial Engineering sector, Germany clearly outperforms as two third 
of its companies display an R&D intensity higher than the average of the upper 
reach, while the relative performance of the UK is not outstanding, as only one 
fourth of its companies exceed this average.  
•  Despite a lower number of companies, Germany also performs relatively better 
than France and the UK also in the Pharmaceuticals and Biotechnology sector. 
Indeed, all German companies have an above-average R&D intensity 
Figure 4.1    Main country and sector distribution of the EU 1000 companies 
    
  
Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD.  
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(compared to that of the top 527 EU companies), while the same holds true for 
about 60% and 50% of French and UK companies, respectively.  
•  Swedish and UK companies in the Software and Computer Services sector show 
high performances as more than 80% display a higher R&D intensity than the 
upper reach average. In Germany, this proportion drops to about 60% while 
only half of the French companies are above this average.  
Although these first observations provide relevant insights, the identification of future 
potential EU leading or top R&D companies deserves further detailed analyses at both 
the sector and company levels. 
 
Trends of companies in the top 10 Member States of the EU 
 
The companies based in the top 10 Member States account for 97.3 % of the total 
R&D of the 1000 EU companies (see table 4.2).  
Among the group of the three top R&D investing countries (accounting for 67.5 % of 
the total R&D), companies based in Germany, the top R&D investor, had a double-
digit average R&D growth, at 11.6 % compared with 9.5% increase in the previous 
year. Companies based in the UK and France increased R&D by 0.5% and 2.3 
respectively, well below the world's average (6.2%). In terms of net sales, German 
and French companies grew by 6.7% and 6.8%, above the world's 4.2% increase. On 
the contrary, UK companies had reduced sales by 1.2%.  The global sales growth of 
the automotive market contributed to the sales growth of German companies, 
showing, in particular, success in exporting to the growing markets of North America 
and Asia Pacific rather than being limited to the shrinking European market of 2012.   
Apart from the group of the three top countries, companies increased R&D above the 
EU average in Italy (18.3 %), Ireland (10.7 %), the Netherlands (7.7 %) and Sweden 
(6.7 %). Among these companies, those based in Italy also had a double-digit growth 
in net sales (11.7%). Companies based in three countries decreased R&D in 2012: 
Finland (-10.3 %), Denmark (-3.0 %) and Spain (-2.1  %). Among these companies, 
those from Finland showed also a decrease of net sales (-1.3%). 
It is important to remember that in many countries, the aggregate country indicators 
depend to a large extent on the figures of a very few firms. This is due, either to the 
country's small number of companies in the Scoreboard or to the concentration of 
R&D in a few large firms. For example: 
•  The R&D growth of Fiat (51.5%), accounting for more than 36 % of the R&D of 
companies based in Italy, contributed a significant part of the R&D growth of that 
country. Fiat’s R&D growth was increased by its acquisition of Chrysler.  
•  Three companies from the Automobiles & Parts sector, accounting for 32% of the 
R&D of companies based in Germany, contributed a large part of the that 
country's R&D growth: Volkswagen (32.1 %), Robert Bosch (16.1 %) and BMW 
(17.2 %). Volkswagen’s R&D growth was increased by its acquisition of Porsche 
and Man. 
•  Similar cases occur in Finland where Nokia's R&D investment accounts for almost 
74% of the total R&D by Finnish companies and in Ireland with Seagate   
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Technology (12.6 %), Covidien (12.5%) and Accenture (11.2%), accounting for 60% 
of the R&D of companies based in Ireland.  
 
 
 
Table 4.2  R&D trends of companies based in the top 10 EU Member States 
Country 
 
 
No. of 
companies 
 
 
 
R&D 
Share 
within EU 
 
R&D one 
year 
growth, % 
 
 
Net sales 
One year 
growth, % 
 
Germany 224  35.1  11.6  6.7 
France 124  17.5  2.3  6.8 
UK 252  14.8  0.5  -1.2 
The Netherlands  55  8.3  7.0  4.1 
Sweden 88  6.1  6.7  0.5 
Italy 46  5.6  18.3  11.7 
Finland 45  3.5  -10.3  -1.3 
Spain 22  2.5  -2.1  3.9 
Denmark 37  2.2  -3.0  10.3 
Ireland 16  1.8  10.3  0.8 
Total EU-10  909  97.3  6.1  4.3 
For the sample of 1000 EU companies. 
Source:   The 2013 EU Industrial R&D Investment Scoreboard. 
               European Commission, JRC/DG RTD. 
 
 
 
 
Long-term performance of companies based in the 3 top EU Member 
States 
The annual growth rates of R&D investment and net sales and profitability of 
companies based in Germany, France and the UK is provided respectively in figures 
4.2, 4.3 and 4.4 for the period 2004-2012. These figures are based on our history 
database comprising R&D and economic indicators over the whole 2004-2012 period 
from the EU 1000 dataset, including 135 from Germany, 81 from France and 122 
from the UK.  
The trends observed in these figures show the behaviour of these companies 
including the effects of the crisis that began in 2008. The following points are 
observed:    
•  Companies based in Germany seem to have recovered the levels of growth of 
R&D investment and net sales prior to the crisis.     
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•  Since 2012, companies based in France have recovered a level of net sales 
similar to that of the period preceding the crisis; however, in terms of R&D 
the recovery observed in 2010-2011 was interrupted in 2012.  
•  For the companies based in the UK, the strong recovery shown in 2010-2011 
was broken up in 2012 for net sales growth but R&D growth resumed from 
the low level reached in 2011.  
•  Sector composition of the country samples to a large extent reflects the 
differences observed in terms of profitability. 
 
 
 
 
 
 
 
 
Figure 4.2    Annual R&D and net sales growth and profitability* by the German 
companies. 
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 * Profitability expressed as companies’ profits as percentage of net sales  
 
Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD.   
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Figure 4.3    Annual R&D and net sales growth and profitability* by the French                     
companies 
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* Profitability expressed as companies’ profits as percentage of net sales   
 
Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD. 
Figure 4.4   Annual R&D and net sales growth and profitability* by the UK companies 
   
Note: for 122 UK out of the EU1000 companies with data for the whole period. 
* Profitability expressed as companies’ profits as percentage of net sales 
   
Source: The 2013 EU Industrial R&D Investment Scoreboard 
 European Commission, JRC/DG RTD.  
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R&D intensity trends by companies based in selected Member States 
  
In 2012, for the second consecutive year, the average R&D intensity of the EU-1000 
companies increased slightly because of the higher increase of R&D investments 
compared to that of net sales, 6.1% vs. 4.3% (see Figure 4.5).  
It is important to remember that a few large but low R&D intensity companies have a 
big effect on some country average R&D intensities. One example is Shell and BP for 
the UK. In the 2012, these companies contributed about 42% of the UK's Scoreboard 
company sales, so practically doubling the average R&D intensity of UK companies 
had they been left out.  
 
 
Figure 4.5. Trends in R&D intensities for EU Scoreboard companies in selected Member 
States 
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5.  Sector focus: Health & biotechnology 2005-13 
 
This chapter reviews the healthcare sector and focuses on therapeutic biotechnology and 
pharmaceuticals and analyses the role of the Scoreboard companies operating in this 
industry. 
 
Key findings 
•  The global biotech market is expected to rise 54% from 2012 to 2017 with 60% being 
therapeutic biotech. This demonstrates the growing importance of biotech in 
replenishing the new drug pipelines of pharmaceutical companies. 
•  The demand for new medicines is growing due to rising and ageing populations and 
the increasing wealth of emerging nations. But pharmaceutical companies over the last 
decade have faced the ‘patent cliff’ of expiring blockbuster patents, increased 
regulation and decreasing productivity of their conventional R&D. At the same time 
technological advances in therapeutic biotech have opened up new opportunities. 
•  The big pharmaceutical companies have responded to these challenges first by 
pharmaceutical acquisitions to reduce costs and then by biotech acquisitions and 
collaborations to enhance their new drug pipelines. The Scoreboard allows us to track 
these changes at company level from 2005 to 2012. 
•  The Scoreboard shows that the therapeutic biotech sector is now dominated by the US 
which has all the top five biotech companies and eight of the top ten. But there are a 
number of examples of EU companies which show both high performance and the 
ability to grow to a sustainable size through well-chosen collaborations. 
 
5.1  Introduction and scope 
This chapter is concerned with the development of R&D-led healthcare companies over 
the last decade from 2005 to 2013. There are two main ICB sectors contributing to 
healthcare R&D – pharmaceuticals & biotechnology and health. These two sectors 
account for just over 20% of the total R&D in the world top 2000 companies but 
constitute two of the eight highest R&D intensity sectors (intensity over 4%). Total health 
sector R&D is only about 12% of the R&D in pharmaceuticals & biotechnology 
We are going to focus on R&D–led healthcar e co mpanie s  s o  we will exclude bi o tech  
companies in non-healthcare applications which account for about 40% of global biotech 
sales. The reason is that therapeutic biotechnology dominates the biotech sector in the 
Scoreboard and is accounting for a larger and larger proportion of the new drugs 
launched by pharmaceutical companies. The health sector will be covered only briefly for 
reasons of space and because the biotech/pharma story is so significant. The area of 
diagnostics, however, will be mentioned towards the end of this chapter because of its 
growing importance in the future of biotech/pharma. Roche is a leader in diagnostics 
which accounts for about one fifth of its revenue.  
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The profile of the global biotechnology sector and the split between sub-sectors 
according to Marketwatch’s 2013 survey is: 
•  The global biotech market is forecast to rise from $304bn in 2012 to $468.1bn in 2017, 
an increase of 54% 
•  The market segmentation in 2012 was 60% medical/healthcare, 13.8% food & 
agriculture, 7% environment & industrial processing and 19.2% services (including 
technology services) 
•  The segmentation by region was the Americas 45.4%, Europe 26.1%, Asia Pacific 
26.1%, the Middle East & Africa 2.4%. There are significant differences between 
regions with the US having 61.6% in healthcare, Europe 68.1% but Japan only 35.9% 
We will be focusing on healthcare in this chapter with particular reference to the growing 
importance of biotech to pharmaceutical companies with up to 50% of new drugs 
expected to come from biotech by 2018 compared to just 12% in 2004 (data from 
EvaluatePharma’s 2013 report). But before discussing the details and the companies 
involved we need to describe the main features of the business environment in which 
these major changes are occurring. 
 
5.2  The business environment for healthcare 
There are four major trends occurring in healthcare which are driving changes in the 
whole business environment. These are: 
•  The increasing demand for healthcare due to ageing populations and the growing 
wealth of developing countries. The proportion of the world population over 60 will 
more than double from 10% in 2000 to 21% in 2050. And in China it will more than 
triple from 10% to 32.8% by 2050. The combination of rising and ageing populations 
and increasing GDP means, according to Ernst & Young, that up to 90% of the growth 
of the pharmaceutical industry will be provided by emerging markets by 2020. 
•  Technological innovations range from biotech drugs or software-driven MRI scanners 
and radiotherapy systems to micromechanical devices like drug-eluting stents and 
robotic-assisted surgery. And coming over the horizon is personalised medicine with 
drugs tailored to a patient’s genetic makeup – this combines diagnostics with tailored 
drugs. These changes have already reduced death rates from heart disease and cancer. 
Now biotech innovations are enabling patients with serious diseases like HIV and 
Hepatitis C to be treated and there are new biotech drugs being developed to treat 
more cancers and serious conditions like rheumatoid arthritis. 
•  Increased regulation and demands for proof of increased efficacy for new drugs have 
occurred as a response to safety concerns and rising costs. The FDA (US Food & Drug 
Administration) tightened up its approval and other procedures in 2007 following 
cases such as the withdrawal of Merck’s painkiller Vioxx in 2004 after it was shown 
that the drug increased the risk of a heart attack. And Pfizer was fined $2.3bn in 2009 
for off-label marketing of its arthritis drug. There has also been a move to introduce 
cost-effectiveness analysis (CEA), particularly in the single-payer health systems of 
Europe. NICE (National Institute of Clinical Excellence) in the UK was an early example 
(1999). CEA supports the notion that higher prices can be charged for more efficacious 
drugs which should encourage R&D.   
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•  The  business response of the big pharmaceutical companies to the challenges of 
patent expiries, increased regulation, reduced R&D productivity (because of the 
increasing difficulties of finding new blockbuster small molecule drugs) and to rapid 
biotech advances has been via increased M&A and collaborations with smaller 
biotechs.  
 
We will expand on the last of these trends to set the scene for the discussion in the next 
section of the trends in R&D, sales and profits of both biotech and pharma companies in 
the Scoreboard from 2005 to 2012 and how these reflect the changes in the healthcare 
landscape and illustrate the way in which different companies have responded to them. 
While global pharmaceutical companies have benefited from the increasing demand for 
new and better drugs, they have also faced a series of challenges over the last decade 
including increased regulation and CEA. The two most serious ones have probably been 
the expiry of patents on a whole series of blockbuster drugs and the decreasing 
productivity of R&D as new blockbusters based on conventional small molecule drugs 
became harder to discover.  
Once a drug loses patent protection generics siphon off up to 90% of its sales. The large 
number of patent expiries occurring between 2010 and 2015 has been termed the ‘patent 
cliff’ and all the major pharmaceutical companies have been affected by it. The ‘cliff’ 
extends from 2010 to 2016. The scale and importance of the cliff is demonstrated by 
Pfizer which, just between 2010 and 2012, lost patent protection on drugs like Lipitor, 
Protonix and Geodon which made up 42% of its revenue. Lipitor was the world’s top 
selling drug with peak revenues of $12.9bn in 2006. And Chemistry World reported last 
July that Eli Lilly is freezing the pay of its employees in 2014 to save money ahead of the 
expiry of two key patents which will cause revenue to fall by 20%. 
Big pharma companies have responded to these massive losses in sales in three main 
ways. Cost cutting, M&As between pharmaceutical companies, more focused R&D and 
refilling of pipelines using biotech drugs from biotech companies (through acquisition and 
collaboration). Cost cutting has involved all the functions of these companies. R&D has 
been reduced in some, such as Pfizer which closed its UK research laboratories in Kent 
which had a long record of innovation including discovering the drug Viagra. Other 
companies used mergers and acquisitions to enable them to reduce the R&D of the newly 
combined companies. In manufacturing there has been a trend to use outside contract 
manufacturing companies with the closure of in-house manufacturing plants. And big 
savings have been made in marketing and selling expenses by co-marketing and 
downsizing sales with ZS Associates estimating that the number of US pharmaceutical 
sales representatives would shrink by 26% from 2007 to 2012. 
In the next section we use the Scoreboard to explore two issues in more detail. These are 
the M&A deals between 2004 and 2013 and the development of new drugs using 
biotechnology. One of the first pharmaceutical companies to understand the importance 
of biotechnology was Roche which, in 1990, took a majority stake in Genentech, the first 
ever therapeutic biotech company which was formed in 1976 in the US. It now owns 
100% of Genentech which is responsible for many of Roche’s pipeline drugs. 
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5.3   A multi-year Scoreboard survey of the biotech/pharma sector  
In this section we use the run of R&D Scoreboards from 2005 to 2013 to track the R&D 
and business performance of biotech and pharma companies. We will first give an 
overview of the whole company set, examine the characteristics of the larger companies 
and then look at the way some typical companies have developed over the decade and 
faced the challenges described in section 2. We will conclude by looking at some mainly 
smaller biotech companies and examining how they have grown and the nature of 
collaborations they have formed with large pharmaceutical companies. 
5.3.1   Pharmaceutical & biotechnology companies in the 2013 Scoreboard 
There are 214 companies in total in the Pharmaceuticals and Biotechnology sector out of 
the world top 2000 included in this year’s Scoreboard. This 10.7% of the companies 
accounts for 18% of the R&D in the Scoreboard and the sector has by far the largest R&D 
intensity (14.4%). There are five companies from the sector in the overall top ten by R&D 
in the Scoreboard, two from Switzerland and three from the US.  
The 214 companies have been assigned either to biotech or pharma. There is inevitably a 
grey area between the two so not all the assignments may be the same as those made in 
stock market classifications such as the Nasdaq sectors. These assignments give us 89 
companies in biotech and 125 in pharma. Table 5.1 gives an overview of the two sectors 
and the contributions of each world region. The US has 74.2% of the biotech companies 
and 86.0% of the R&D. The EU has 20.2% of the companies and 9.9% of the R&D so the 
EU companies are on average much smaller. In pharmaceuticals the US has 26.4% of the 
companies but 38.4% of the R&D whereas the EU has 32.0% of the companies but 30.0% 
of the R&D.  
 
Table 5.1 Overview of the Scoreboard companies in the Pharmaceuticals & 
Biotechnology sector       
   EU  US  Others  World  
Biotechnology             
No. companies  18  66  5  89 
Employees  18,832  67,986  17,269  104,087 
R&D investment, € m  1,190  10,300  445  12,000 
Net Sales, € m  5,450  40,100  4,890  50,400 
R&D intensity 
(*)  17%  25%  9%  23% 
Profitability 
(*)  13%  28%  24%  26% 
Pharmaceuticals  
No. companies  40  33  52  125 
Employees  596,006  589,294  529,622  1,714,922 
R&D investment, € m  26,500  33,700  27,500  87,700 
Net Sales, € m  192,000  225,000  208,000  624,000 
R&D intensity 
(*)  14%  15%  13%  14% 
Profitability 
(*)  19%  23%  16%  19% 
 
   
 
The 2013 EU Industrial R&D Investment Scoreboard 61
 
Given the large number of companies we will focus on the top 25 in each category and 
use the run of Scoreboards to understand some of the big changes that have occurred 
over the last eight years in response to the challenges we outlined in section 5.2.  
 
5.3.2    Sector trends 2005-2012 
R&D in both the biotech and pharma sub-sectors is dominated by the larger companies. 
For example, the top 10 biotechs account for 63% of the R&D of all 89 companies while 
the top 10 pharmas account for 58% of the R&D of all 125 companies. The characteristics 
of the top 30 companies from each subsector are: 
•  Biotechnology: Top 30 companies by R&D with R&D ranging from €62m (and sales 
€0.8m) to R&D of €2.3bn (and sales €12.6bn). A total of 25 of these companies are 
from the US, 4 from the EU and one from Australia. All are in therapeutic biotech 
except two of those from the EU – Novozymes in industrial biotech (enzymes) and 
Qiagen (sample and assay technologies).  
•  Pharmaceuticals: Top 30 companies by R&D with R&D ranging from €0.33bn (and sales 
€2bn) to R&D of €7bn (and sales €37.8bn). A total of 9 of these are from the US, 13 
from Europe (10 from the EU and 3 from Switzerland), 7 from Japan and one from 
Israel. 
The relative numbers of EU and US companies in the two sectors show that the US 
dominates the world in larger therapeutic biotech companies and that Japan lags behind 
the EU in both areas.  
Now the companies in the top ranks have changed markedly from 2005 to 2013. To 
understand this we will discuss M&As in the pharma sector, the rise of biotechnology and 
the modes of collaboration between big pharma companies and smaller, growing 
companies that are mainly biotechs. 
 
M&As between large pharmaceutical and biotech companies 
Some of the trends in the pharmaceutical sector can be seen from a comparison of the 
top 25 in 2005 and 2012. Of the top 25 pharmaceutical companies by R&D in 2005, only 
17 made it into the top 25 of 2012. This was because five of them were acquired while 
the R&D of the other three did not increase enough to reach the top 25 of 2012. Wyeth 
was acquired by Pfizer for €45.5bn, Schering by Bayer for €17bn, Schering-Plough by 
Merck (US) for €25.5bn, Altana by Nycomed for €4.6bn and Schwarz Pharma by UCB for 
€3.8bn. Pfizer had already acquired Warner-Lambert in 2000 and Pharmacia in 2003. 
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Table 5.2 Top 25 Pharmaceutical  R&D investors in 2005 seven year later 
 
Company  Country R&D 
2012/2005 
World
Rank 
2005 
World Rank 2012
Pfizer  USA  91%  2  10 
Johnson & Johnson  USA 109%  7  9 
GlaxoSmithKline  UK  93%  10  20 
Novartis  Switzerland 169%  13  7 
Sanofi-Aventis  France  121%  16  15 
Roche  Switzerland 191%  19  6 
Merck US  USA  184%  21  8 
AstraZeneca  UK 118%  28  33 
Eli Lilly  USA  156%  32  26 
Wyeth  USA  -  36  Acquired by Pfizer - Deal value: 45,536,102 th 
EUR 
Bristol-Myers Squibb  USA  122%  37  40 
Bayer  Germany 169%  46  36 
Schering-Plough  USA  -  56  Merged with Merck US - Deal value: 25,487,802 
th EUR 
Abbott Laboratories  USA 212%  58  35 
Boehringer Ingelheim  Germany  206%  61  42 
Takeda Pharmaceutical  Japan 280%  74  41 
Schering  Germany  -  77  Acquired by Bayer AG - Deal value: 17,000,000 th 
EUR 
Merck DE  Germany 212%  97  73 
Novo Nordisk  Denmark  205%  101  79 
Eisai  Japan 187%  121  108 
UCB  Belgium  153%  133  146 
ALTANA  Germany  -  146  Acquired by Nycomed - Deal value: 4,600,000 th 
EUR 
Yamanouchi 
Pharmaceutical  
Japan  -  156  70 (now Astellas Pharma Inc., they merged with 
Fujisawa Pharmaceutical Co., Ltd) 
Mitsubishi Pharma  Japan  -  169  Now controlled by Mitsubishi Chemical Holdings 
Co. 
Forest Laboratories  USA  194%  177  162 
Allergan  USA 226%  185  149 
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Table 5.3 Top 25 Biotechnology specialised R&D investors in 2005 seven year later 
 
Company  Country R&D 
2012/2005 
World
Rank 
2005 
World 
Rank 2012 
Amgen  USA  131%  45  47 
Biogen Idec  USA 160%  110  111 
Serono  Switzerland    129  Acquired by Merck DE  - Deal value: 4,737,838 th 
EUR 
Genzyme  USA    158  Acquired by  Sanofi-Aventis - Deal value: 14,055,061 
th EUR 
Chiron  USA    173  Acquired by Novartis AG - Deal value:  4,304,064 th 
EUR 
MedImmune  USA    190  Acquired by  AstraZeneca - Deal value:  11,387,012 
th EUR 
Applera  USA    220  Acquired by Invitrogen (now Life Technologies 
Corporation) 
Millennium 
Pharmaceuticals 
USA    230  Acquired by Takeda America Holdings - Deal value:  
5,675,120 th EUR 
Kyowa Hakko Kogyo  Japan    255  Now controlled by Kirin Holdings Co. Ltd. 
Gilead Sciences  USA 567%  259  82 
Human Genome 
Sciences 
USA    328  Acquired by  GlaxoSmithKline - Deal value: 
2,463,689 th EUR 
Protein Design Labs  USA   383  No more in Scoreboard 
Merial  UK    417  Acquired by  Sanofi-Avensis  - Deal value:  2,713,329 
th EUR 
Celgene  USA 951%  421  88 
Medarex  USA    451  Acquired by Bristol-Myers Squibb - Deal value:  
1,674,610 th EUR
Theravance  USA 83%  482  793 
OSI Pharmaceuticals  USA    484  Acquired by  Astellas Pharma  - Deal value:  
3,343,026 th EUR 
Novozymes  Denmark 182% 490  425 
Abgenix  USA    507  Acquired by Amgen.  - Deal value: 2,187,840 th EUR 
CV Therapeutics  USA    540  Acquired by Gilead Sciences - Deal value:  1,062,355 
th EUR 
Vertex Pharmaceuticals  USA  623%  546  178 
CSL  Australia 309% 557  330 
NPS Pharmaceuticals  USA  81%  567  925 
Regeneron 
Pharmaceuticals 
USA 114%  571  720 
Invitrogen  USA    589  346 (now Life Technologies Corporation, under 
acquisition by Thermo Fisher Scientific Inc. HERMO 
FISHER SCIENTIFIC INC. - Health Care Equipment & 
Services) 
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Despite this acquisition activity, there was only a modest increase in R&D from 2005 to 
2012 for many of the large pharmaceutical companies. Pfizer’s R&D actually decreased 
over these eight years while that of AstraZeneca, GlaxoSmithKline and Sanofi increased by 
less than 25%. 
The pace of change was even faster in biotech. Of the top 25 biotechs of 2005 shown in the 
Scoreboard, only eight survived to 2012 (one under a new name) and two of them were 
not therapeutic biotechs (Novozymes and Qiagen). The fate of the other 17 is summarised 
below: 
- Ten biotechs were acquired by pharmaceutical companies (three by Sanofi, two by 
AstraZeneca and one each by GSK, Johnson & Johnson, Merck,  Novartis  and  Takeda)                
- One was acquired by another biotech (Agennix)         
- Six did not make the 2013 Scoreboard (one being a demerger) 
We should also mention that, in 2009, Roche acquired full ownership of Genentech for 
$46.8bn (it already had a majority shareholding). The increases in R&D amongst profitable 
biotechs were also very large. There are 14 biotechs appearing in the 2013 Scoreboard 
which both tripled R&D from 2005 to 2012 and had a positive profitability of at least 4%. 
These are shown in table 5.4. 
Table 5.4. Top 14 high performance biotech companies
Bio SB R&D 2012 R&D 
intensity
R&D Profitabil
ity
Empl.  
2012
Rank Rank (mil €) 2012 growth 2012
GILEAD SCIENCES INC 2 82 US 1334 19% 504% 43% 5000
CELGENE CORP 3 88 US 1206 29% 914% 35% 4700
LIFE TECHNOLOGIES CORPORATION 7 346 US 259 9% 250% 19% 10000
ILLUMINA INC 11 460 US 175 20% 692% 22% 2400
UNITED THERAPEUTICS CORP 13 572 US 131 19% 381% 46% 623
ALKERMES PLC 16 702 IE 101 23% 3322% 14% 1230
EMERGENT BIOSOLUTIONS INC. 21 783 US 91 43% 554% 11% 877
VIROPHARMA INC 38 1154 US 51 16% 538% 8% 410
BTG PLC 39 1185 UK 49 18% 383% 9% 569
ACORDA THERAPEUTICS, INC. 50 1362 US 41 18% 318% 8% 378
GENUS PLC 58 1486 UK 36 9% 394% 16% 2189
GENOMIC HEALTH, INC. 60 1501 US 36 20% 422% 4% 612
SPECTRUM PHARMACEUTICALS, INC. 65 1601 US 32 16% 216% 31% 193
LUMINEX CORP 70 1646 US 31 20% 628% 11% 709
Company Country
 
 
Table 5.4 shows key data for Gilead Sciences, Celgene, Life Technologies, Illumina, United 
Therapeutics, Alkermes, Emergent Biosolutions, Viropharma, BTG, Acorda Therapeutics, 
Genus, Genomic Health, Spectrum Pharmaceuticals and Luminex.  
The first six of these are large biotechs since they feature in the top 14 biotechs by R&D in 
this year’s Scoreboard with Gilead Sciences and Celgene in second and third places. Amgen 
remains at #1 as in 2005 with Biogen Idec as #4 (#2 in 2005). Of the 14 biotechs, eleven are 
from the US, two from the UK and one from Ireland.  
The message of this chapter is that large pharmaceutical companies have adopted two 
strategies in the last decade to overcome the challenges outlined in section 2. The first was   
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the acquisition of other pharmaceutical companies, primarily to reduce costs. The second 
has been the bolstering of their pipelines through the acquisition of biotech companies or 
collaborations with them.  We now look at the modes of collaboration between the two. 
 
5.3.3   Collaboration between biotech and pharma companies 
The biotechnology industry was started in 1976 with the foundation of Genentech which 
now employs some 12,500 people and, since 2009, is 100% owned by Roche, an example of 
acquisition as an extreme form of collaboration. We have seen above how eleven of the 
top 25 biotechs in 2005 were acquired, ten by pharmaceutical companies. Acquisitions of 
this type will undoubtedly continue but other types of collaboration are important for small 
biotechs that aim to grow fast but also remain independent. This type of collaboration is 
particularly important for smaller EU biotechs which need to grow larger to compete 
effectively with the many larger US ones.  
We will illustrate four different modes of collaboration with examples of biotech 
companies that are growing in these four ways. The data is mainly taken from the 
companies’ own websites. 
•  The first is Abcam, a biotech which illustrates the use of marketing collaborations used 
to expand its internet sales. It is a £122m sales Cambridge company that supplies 
antibodies and proteins to therapeutic and other biotech researchers all over the world 
through its innovative website which offers 122,000 products. It develops and makes 
only one third of its products with the other two-thirds sourced through collaborations. 
It provides comprehensive technical data sheets and quality control for these products 
which are all marketed through its website. Its growth has been mainly organic but with 
related acquisitions. Abcam had a September 2013 cash pile of over £38m with no debt. 
 
•  The second is MorphoSys, a biotech which has a pipeline of 81 potential drugs based on 
antibodies with 21 of these already in clinical trials. It is collaborating with several 
pharmaceutical companies on pipeline drugs and derives income from these through 
licence fees and milestone payments and will gain royalty streams when new partnered 
drugs are launched. Partners include Bayer, GSK, Johnson & Johnson, Novartis, Pfizer 
and Roche. It also funds development of certain proprietary drugs out of its own cash 
resources so that it can agree more lucrative partnerships for these at a later stage 
(clinical Phase II or III). It has just signed deals with GSK and Celgene for its two most 
advanced drugs. Even before these deals MorphoSys had a cash pile of €166m. 
 
•  The third is Oxford Nanopore which is developing novel DNA and RNA sequencing 
instruments one of which will sell for less than $1,000. It is a private company valued at 
£328m in June 2013 and was spun out of Oxford University by IP Group, a university 
research commercialisation company. Oxford Nanopore has just raised another £40m of 
funds for further growth. University commercialisation companies such as IP Group, 
Fusion IP and Imperial Innovations are helping to spin out new companies from 
university R&D in biotech and many other R&D-intensive sectors and then manage their 
growth to a viable size at which they can be listed. 
 
•  The fourth is Regeneron Pharmaceuticals, a US biotech specialising in antibody-derived 
drugs that illustrates collaborations with EU pharmaceutical companies. It has its first  
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blockbuster drug on the market – Eylea – and has at least three more potential 
blockbusters in its pipeline. It collaborates with Bayer on Eylea with Bayer marketing the 
drug outside the US and Regeneron retaining full US rights. Regeneron is also 
collaborating with Sanofi on the joint development of other drugs for diseases such as 
asthma and rheumatoid arthritis. Sanofi has a 16% shareholding in Regeneron and can 
increase this to 30% under their existing agreement. 
 
These four examples illustrate the different ways in which smaller biotechs can grow to a 
size where they can be self-sustaining through generating enough cash to fund the 
development of a strong pipeline and arrange beneficial terms for marketing their 
successful drugs or devices. Accumulating an adequate cash pile is an important step in this 
process. 
 
 
5.4   The prospects for therapeutic biotech companies 
It is clear from the previous sections that biotechnology is of increasing importance and is 
likely to be generating over 50% of new drugs by 2018. The US dominates therapeutic 
biotechnology, the largest segment of biotechnology. It is home to all five of the top 
biotechs with R&D over €500m and to nine of the top ten. European and other 
pharmaceutical companies have realised the importance of biotech as the likely source of 
the majority of new drugs in the future. They have therefore acquired biotech companies 
and collaborated with them in various ways. 
However, Europe has a proud record of scientific discovery in biotech including such 
milestones as the structure of DNA and the discovery of antibodies. Europe would benefit 
from having some larger and independent biotech companies to build up its base of skills 
and commercial expertise in this important sector to gain full commercial benefits from its 
fundamental R&D. This chapter illustrates some of the ways in which this can be done 
ranging from university spin-out companies growing under the umbrella of 
commercialisation companies to the development of a well-stocked biotech pipeline using 
a combination of early and late stage partnerships with pharmaceutical companies. 
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6.  Company foreign direct investments    
 
This chapter looks at the foreign direct investments (FDIs) of Scoreboard companies as a 
proxy of their internationalization strategies.  
FDI is defined as an investment made to acquire lasting interest in enterprises operating 
outside of the economy of the investor. The UN defines control in this case as owning 
10% or more of the ordinary shares or voting power of an incorporated firm or its 
equivalent for an unincorporated firm. Additional to having an equity capital or 
reinvested earnings in an enterprise, there are other ways in which foreign investors may 
acquire an effective voice in the management of an enterprise. These include franchising, 
subcontracting, management contracts, turnkey arrangements
12, leasing, licensing and 
production-sharing.  
There are two types of FDIs used for market entry purposes: greenfield FDIs and mergers 
and acquisitions (M&As). 
Although greenfield FDI projects account for a much smaller share in the total value of 
FDI, the number of greenfield projects greatly surpasses the number of M&A projects 
(World Investment Report, UNCTAD, 2012).  
Greenfield Foreign Direct Investments consist in the expansion of existing facilities or a direct 
investment in new facilities (in an area where no previous facilities exist). Greenfield FDIs are 
the primary objective of a host nation’s promotional efforts, as they create new production 
capacity and jobs, transfer technology and know-how, and can lead to linkages to the global 
marketplace. Investing companies, on the other hand, have aims such as lowering costs, 
avoiding tariff barriers, using local skills and incentives and understanding the specific needs 
of local markets. 
Matching the first 1500 Scoreboard companies
13 with data on greenfield FDIs
14, the 
objective is to show how the top world R&D spenders are locating and re-organizing their 
industrial activities (e.g., manufacturing, research, development and testing) around the 
world and across sectors through outflows of FDIs.  
 
 
 
Key Findings 
•  The EU plays a major role in the international scenario both as the main source 
and destination of knowledge intensive FDIs.  22% of the total number of FDIs in 
R&D is destined to the EU, while the US receives only 8 % of projects in R&D.  
•  Six out of the ten countries with the highest number of international projects are 
European.  
•  The EU attracts more technological intensive projects than resource-saving 
investments compared to the other economies.  
•  FDIs in R&D are concentrated mainly in the three sectors of Technology Hardware 
and Equipment, Automobiles & Parts and Pharmaceuticals & Biotechnology. 
 
                                                       
12 A turnkey contract is a business arrangement in which a project is delivered in a completed state. Rather than contracting with 
an owner to develop a project in stages, the developer is hired to finish the entire project without owner input. 
13  Sample corresponding to the 2012 EU Industrial R&D Investment Scoreboard edition. 
14 Greenfield investment data is derived from the © 2013 fDi Markets database (a service from the Financial Times 
Limited 2013), which accounts for more than 110,000 greenfield investment projects around the world for the period 
2003-2011. Information on the greenfield FDI project is derived from different media sources and can be interpreted as 
a commitment to invest validated with company sources.  
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Overview of Scoreboard Greenfield FDIs  
 
The total number of greenfield FDI projects undertaken during the period 2003-2012 by 
the world top 1500 R&D investors is 27,208 for a total capital expenditure of 2.03 trillion 
Euros. 
For the purpose of the analysis, intra-European FDIs and intra-state US investments are 
excluded. 
The breakdown of FDIs by activity and geographical area and the growth rates over the 
period of the different categories of investments (manufacturing, R&D and others) are 
presented in Table 6.1.  
 
Greenfield FDIs in manufacturing activities represent the highest share, both in terms of 
value (60% of total capital investments) and number of projects (39%). The shares for FDIs 
on R&D are 5% and 12% respectively.  
 
Table 6.1: Decomposition of FDIs by activity 
 
 
FDI type  N. of projects   € bn 
Manufacturing  10514 1219
Sales & Marketing  4311 36
Research & Development  3342 97
Retail 2035 42
Logistics, Distribution & Transport.  1270 83
Business Services  1229 31
Headquarters 1086 29
Maintenance & Services  559 8
ICT & Internet Infrastructure  540 80
Education & Training  475 5
Extraction 474 254
Customer Contact  352 3
Electricity 343 110
Technical Support  277 3
Shared Services  228 4
Construction 123 24
Recycling 50 2
Total 27208 2030
 
 
Source 
Region 
Outflows 
(% € 2030 bn) 
Projects 
(% of 27208) 
Destination 
Region 
Inflows   
(% € 2030 bn)  
Projects 
(% of 27208) 
Asian Tigers  7  4 Asian Tigers  5  6
BRICS 7  4 BRICS  34  34
EU   42  36 EU   9  17
Japan 14  19 Latin  America  8  6
RoW 2  2 RoW  18  13
Switzerland 2  4 South  Asia 17  14
USA   25  30 USA   8  10  
Source: The 2013 EU Industrial R&D Investment Scoreboard,  European Commission, JRC/DG RTD. 
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Looking at the geographical distribution, top EU R&D investors appear as the main 
source of greenfield FDIs, both in terms of value (42% of the total versus 25% for their 
US counterparts) and of number of projects (36% versus 30% for US top R&D 
investors). These figures confirm the important role played by the EU as the main 
source of FDIs
15. In terms of destination, BRICS countries (Brazil, Russia, India, China 
and South Africa) appear to be the main beneficiaries (34% of total value and 34% of 
the total number of projects). The EU attracts 9% of the value and 17% of the projects 
(versus 8% and 10% respectively for the US).  
 
Table 6.2 highlights the top 10 European (red) and non-European (black) countries 
responsible for the larger shares of worldwide direct investment flows. The table 
reports the number of investment projects, estimated capital expenditure (in billions 
of Euro) and estimated number of jobs created (in thousands).  
 
 
Table 6.2: FDI outflows and inflows, 2003-2012 
Top 10 source countries (86% of total n. of projects) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Top 10 destination countries (55 % of total n. of projects) 
Destination Country  N. of projects € bn Jobs (x1000) 
China  4353 325 1522 
United States  2618 166 410 
India  2505 142 902 
Russia  1162 81 366 
Brazil  980 131 411 
UK  817 29 95 
Singapore  681 44 114 
Mexico  660 54 268 
Canada  616 72 96 
Thailand  613 26 205   
Source Region  N. of projects  € bn Jobs (x1000) 
United States  8252 505 1808 
Japan  5156 289 1437 
Germany  3291 205 890 
France  1672 164 440 
UK  1526 131 392 
Switzerland  1180 43 203 
South Korea  769 96 364 
Netherlands  662 99 157 
Sweden  534 18 110 
Italy  499 69 170 
Source: The 2013 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD. 
 
                                                       
15 Analysing a different sample, similar results have been reported by the "Foreign direct investment statistics" (Eurostat), 
http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/Foreign_direct_investment_statistics.  
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The two top investing countries are the US and Japan, followed by a set of EU 
countries: Germany, France, and the UK. Also, the last three top 10 investing countries 
are the Netherlands, Sweden, and Italy. 
In contrast, the top destination countries are the emerging economies of China, India, 
Russia, and Brazil, and the US (in second place). The estimated number of jobs that are 
expected to be created by the FDI projects is proportionate to their magnitude. 
Moreover, most of the jobs are estimated to be created by US projects and expected 
to be created in China. 
 
 
 
Locating R&D abroad: how attractive is the EU for greenfield FDI? 
 
Table 6.3 shows the flows of FDI in R&D from region to region. BRICS and European 
countries are the most attractive: top R&D investors locate 41% of their total number of FDIs 
in R&D in the BRICS and 22% in the EU (we exclude in this account intra-EU flows, to make it 
comparable with other world regions). In comparison, the US receives only 8 % of R&D 
projects. Considering the geographical location of the companies performing such FDI in 
R&D, 26% of the projects originate in Europe, 11% in Japan, and 52% in the US.   
 
Table 6.3: Flows of FDIs in R&D, 2003-2012 (% of n. of projects) 
  Destination Region   
Source Region  Asian Tigers  BRICS  EU  Latin Am  RoW  South Asia  USA  Total 
Asian Tigers           0.09           1.65          0.57           -         0.18     0.12        0.72       3.32 
EU           2.60          12.39             -         0.84        3.05     2.12        4.61     25.61 
Japan           1.38           3.92          2.63        0.03        0.33     1.14        2.03     11.46 
RoW           0.03           0.39          0.51        0.03        0.15        -        0.15       1.26 
Switzerland           0.42           1.32          1.20        0.09        0.45     0.03        0.51       4.01 
USA           4.61          20.89        15.83        1.94        4.67     3.83           -      51.77 
BRICS           0.09           0.48          1.11        0.18        0.33     0.18        0.21       2.57 
Total           9.22          41.02        21.84        3.11        9.16     7.42        8.23  3,342  
     
Source: The 2013 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD. 
 
Table 6.4 displays in more detail the destination of the 856 FDI projects in R&D made by the 
EU Scoreboard companies during the period 2003-2012. The main destinations are the BRICS 
(49% of projects and 48% of the total capital investment) and the US (18% and 21%, 
respectively).  
 
Table 6.5 mirrors the same exercise, analysing the inflows of R&D projects undertaken by 
non-EU Scoreboard companies into EU countries. The vast majority of the total number of 
projects comes from US companies (72%), and from Japan (12%). Similar figures are found 
for capital expenditure (73% and 10% of €16.2bn, respectively).  
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Table 6.4: Where do EU Companies locate R&D investment? 
   
 
 
 
 
 
 
 
           
Source  N. of projects Capex (€ bn) 
USA 1730 48.8 
EU   856 25.4 
Japan 383 8.2 
Switzerland 134 6.6 
Asian Tigers  111 3.8 
BRICS 86 3.1 
RoW 42 0.9 
Source: The 2013 EU Industrial R&D Investment Scoreboard,  European Commission, JRC/DG RTD. 
 
 
Table 6.5: From which companies do EU receive FDI in R&D? 
 
 
 
 
 
 
 
 
 
          
destination  N. of projects  Capex (€ bn) 
BRICS 1371 44.4 
EU   730 16.2 
USA   308 9.6 
RoW 306 9.0 
Asian Tigers  275 8.6 
South Asia  248 5.2 
Latin America  104 3.8 
Source: The 2013 EU Industrial R&D Investment Scoreboard,  European Commission, JRC/DG RTD. 
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Figure 6.6 compares the inflows and outflows of FDIs in R&D and manufacturing, across 
geographical areas. The top two pie charts report the percentages of the total number of 
project outflows, while the bottom pie charts represent the inflows, as a percentage of 
projects. Comparing R&D inflows and outflows, figures show that the EU has a more 
balanced account (4% net outflow) than the US (44% net outflow). If we compare the inflow 
shares of the two types of projects, manufacturing and R&D, we observe that the EU has a 
larger share of the more knowledge-intensive projects (R&D) than resource-saving 
investments (manufacturing). Concretely, the difference between these two shares is 7%, 
larger than for any other world region (BRICS 1%, Asian Tigers 5%, RoW 0%, USA -3%, South 
Asia -6%, and Latin America -4%).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: Inflows and outflows of FDIs in R&D and manufacturing by region, 2003-2012 
 
   
         
 
Source:  The 2013 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.   
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Sector distribution of FDIs in R&D 
The identification of the key industrial sectors in which the top R&D spenders of the 
Scoreboard allocate their investments abroad has been made on the basis of a sample of 
companies for which data is available for the period 2003-2012.  
 
Figure 6.7 reports the number of projects by type of FDI (R&D versus manufacturing and 
other types of FDIs
16) and R&D intensity (high, medium-high, medium-low, and low R&D 
intensity, see Box 1.1). The quasi totality (94%) of FDI projects in R&D from US companies 
are performed by companies from high and medium-high R&D intensity sectors. This 
confirms the importance of such investments as drivers for knowledge enhancement. In 
the EU, this percentage reduces to 83%. EU companies have a larger number of projects in 
manufacturing compared to the US (nearly 3.5 versus 2.6 thousand). Most of the projects 
come from companies belonging to medium-high and low R&D intensity sectors (67% and 
20%, respectively) for the EU and medium-high and high ones (65% and 21%, respectively) 
for the US. The other types of FDIs exhibit diverging directions, with the bulk of EU projects 
originating from medium-low and low R&D-intensive sectors (54%), while the vast majority 
of US projects (90%) come from companies belonging to high and medium-high ones.  
 
In general, these figures confirm the strategic importance of FDIs for firms operating in 
more intensive R&D sectors.  
 
 
Figure 6.7: Number of FDI projects (2003-2012), by type and sector group. 
 
   
Source: The 2013 EU Industrial R&D Investment Scoreboard,  European Commission, JRC/DG RTD. 
                                                       
16 The other types of FDIs are: sales & marketing, retail, logistics, distribution & transportation, business services, headquarters activities, 
maintenance & services, ICT & internet infrastructures, education & training, extraction, customer contact, electricity, technical support, shared 
services, construction, recycling.  
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Figure 6.8 reports on the industries and regions that originate the highest volumes of FDI 
capital expenditure in R&D activities. As the graph shows, most of the investments in R&D 
(60% of the total capital investment of €97.0bn) are concentrated in ICT (production and 
services), Pharmaceuticals & Biotechnology, and Automobiles & Parts. These results are in 
line with the findings of another recent study from the European Commission
17, which 
reports evidence on how foreign innovation-related activities, including R&D are heavily 
concentrated in terms of sectors. 
 
Figure 6.8  R&D FDIs outflows by sector and region, 2003-2012 (€ bn) 
 
 
Source: The 2013 EU Industrial R&D Investment Scoreboard,  European Commission, JRC/DG RTD. 
 
The main actors of this knowledge-seeking type of investment are the US and EU, Japan 
mainly for the automobiles industry and Switzerland for ICT production and 
Pharmaceuticals. This suggests that advanced economies are getting access to 
technological complementary knowledge by investing abroad. 
 
                                                       
17 “The role and internationalisation strategies of multinational companies in innovation”, 2013 DG ENTR 
http://ec.europa.eu/enterprise/policies/innovation/files/proinno/innovation-intelligence-study-6_en.pdf   
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Annex 1 - Background information 
The Scoreboard is part of the European Commission’s monitoring activities to improve the 
understanding of trends in R&D investment by the private sector and the factors affecting it. 
It was created in response to the Commission’s Research Investment Action Plan
18, which 
aims to help close the gap between the EU’s R&D investment and that of other developed 
economies. 
The annual publication of the Scoreboard is intended to raise awareness of the importance of 
R&D for businesses and to encourage firms to disclose information about their R&D 
investments and other intangible assets. 
The data for the Scoreboard are taken from companies’ publicly available audited accounts. 
As in more than 99% of cases these accounts do not include information on the place where 
R&D is actually performed, the company’s whole R&D investment in the Scoreboard is 
attributed to the country in which it has its registered office
19. This should be borne in mind 
when interpreting the Scoreboard’s country classifications and analyses.  
The Scoreboard’s approach is, therefore, fundamentally different
20 from that of statistical 
offices or the OECD when preparing Business Enterprise Expenditure on R&D (BERD) data, 
which are specific to a given territory. The Scoreboard data are primarily of interest to those 
concerned with benchmarking company commitments and performance (e.g. companies, 
investors and policymakers), while BERD data are primarily used by economists, governments 
and international organisations interested in the R&D performance of territorial units defined 
by political boundaries. The two approaches are therefore complementary. The 
methodological approach of the Scoreboard, its scope and limitations are further detailed in 
Annex 2 below.   
 
 
Scope and target audience 
The Scoreboard is a benchmarking tool which provides reliable up-to-date information on 
R&D investment and other economic and financial data, with a unique EU-focus. The 2000 
companies listed in this year’s Scoreboard account for more than 90%
21 of worldwide 
business enterprise expenditure on R&D (BERD). The data in the Scoreboard are published as 
a four-year time-series to allow further trend analyses to be carried out, for instance, to 
examine links between R&D and business performance. 
The Scoreboard is aimed at three main audiences.  
• Companies can use the Scoreboard to benchmark their R&D investments and so find where 
they stand in the EU and in the global industrial R&D landscape. This information could be of 
value in shaping business or R&D strategy.  
• Investors and financial analysts can use the Scoreboard to assess investment opportunities 
and risks. 
                                                       
18 “Investing in research: an action plan for Europe”, COM(2003)266, http://europa.eu.int/eur-lex/en/com/cnc/2003/com2003_0226en02.pdf.  
19 The registered office is the company address notified to the official company registry. It is normally the place where a company's books are 
kept. 
20 The Scoreboard refers to all R&D financed by a company from its own funds, regardless of where the R&D is performed. BERD refers to all R&D 
activities performed by businesses within a particular sector and territory, regardless of the location of the business’s headquarters, and 
regardless of the sources of finance. The sources of data also differ: the Scoreboard collects data from audited financial accounts and reports 
whereas BERD typically takes a stratified sample, covering all large companies and a representative sample of smaller companies. Additional 
differences concern the definition of R&D intensity (BERD uses the percentage of R&D in value added, while the Scoreboard considers the 
R&D/Sales ratio) and the sectoral classification (BERD uses NACE (the European statistical classification of economic sectors), while the 
Scoreboard uses the ICB (the International Classification Benchmark). 
21 According to latest Eurostat statistics. However BERD and Scoreboard figures are not directly comparable.  
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• Policy-makers,  government and business organisations can use R&D investment 
information as an input to policy formulation or other R&D-related actions.  
Furthermore, the Scoreboard dataset has been made freely accessible so as to encourage 
further economic and financial analyses and research by any interested parties. 
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Annex 2 - Methodological notes 
 
The data for the ranking of the 2013 EU Industrial R&D Scoreboard (the Scoreboard) have 
been collected from companies' annual reports and accounts by Bureau van Dijk Electronic 
Publishing GmbH (BvD). The source documents, annual reports & accounts, are public 
domain documents and so the Scoreboard is capable of independent replication. In order to 
ensure consistency with our previous Scoreboards, BvD data for the years prior to 2012 have 
been checked with the corresponding data of the previous Scoreboards adjusted for the 
corresponding exchange rates of the annual reports.  
 
 
Main characteristics of the data 
The data correspond to companies' latest published accounts, intended to be their 2012 
fiscal year accounts, although due to different accounting practices throughout the world, 
they also include accounts ending on a range of dates between late 2011 and early 2013.  
Furthermore, the accounts of some companies are publicly available more promptly than 
others. Therefore, the current set represents a heterogeneous set of timed data. 
In order to maximise completeness and avoid double counting, the consolidated group 
accounts of the ultimate parent company are used. Companies which are subsidiaries of any 
other company are not listed separately. Where consolidated group accounts of the ultimate 
parent company are not available, subsidiaries are included. 
In case of a demerger, the full history of the continuing entity is included. The history of the 
demerged company can only go back as far as the date of the demerger to avoid double 
counting of figures. 
In case of an acquisition or merger, pro forma figures for the year of acquisition are used 
along with pro-forma comparative figures if available.  
The R&D investment included in the Scoreboard is the cash investment which is funded by 
the companies themselves. It excludes R&D undertaken under contract for customers such as 
governments or other companies. It also excludes the companies' share of any associated 
company or joint venture R&D investment when disclosed. Where part or all of R&D costs 
have been capitalised, the additions to the appropriate intangible assets are included to 
calculate the cash investment and any amortisation eliminated. 
Companies are allocated to the country of their registered office. In some cases this is 
different from the operational or R&D headquarters. This means that the results are 
independent of the actual location of the R&D activity.  
Companies are in industry sectors according to the NACE Rev. 2
22 and the ICB (Industry 
Classification Benchmark). 
 
Limitations 
 
                                                       
22 NACE is the acronyme for “Nomenclature statistique des activités économiques dans la Communauté européenne”.  
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The  Scoreboard relies on disclosure of R&D investment in published annual reports and 
accounts. Therefore, companies which do not disclose figures for R&D investment or which 
disclose only figures which are not material enough are not included in the Scoreboard. Due 
to different national accounting standards and disclosure practice, companies of some 
countries are less likely than others to disclose R&D investment consistently.  
In some countries, R&D costs are very often integrated with other operational costs and can 
therefore not be identified separately. For example, companies from many Southern 
European countries or the new Member States are under-represented in the Scoreboard. On 
the other side, UK companies are over-represented in the Scoreboard.  
For listed companies, country representation will improve with IFRS adoption. 
The R&D investment disclosed in some companies' accounts follows the US practice of 
including engineering costs relating to product improvement. Where these engineering costs 
have been disclosed separately, they have been excluded from the Scoreboard. However, the 
incidence of non-disclosure is uncertain and the impact of this practice is a possible 
overstatement of some overseas R&D investment figures in comparison with the EU.  
Where R&D income can be clearly identified as a result of customer contracts it is deducted 
from the R&D expense stated in the annual report, so that the R&D investment included in 
the Scoreboard excludes R&D undertaken under contract for customers such as governments 
or other companies. However, the disclosure practise differs and R&D income from customer 
contracts cannot always be clearly identified.  This means a possible overstatement of some 
R&D investment figures in the Scoreboard for companies with directly R&D related income 
where this is not disclosed in the annual report. 
In implementing the definition of R&D, companies exhibit variability arising from a number of 
sources: i) different interpretations of the R&D definition. Some companies view a process as 
an R&D process while other companies may view the same process as an engineering or 
other process; ii) different companies' information systems for measuring the costs 
associated with R&D processes; iii) different countries' fiscal treatment of costs. 
 
 
Interpretation 
There are some fundamental aspects of the Scoreboard which affect their interpretation. 
The focus of the Scoreboard on R&D investment as reported in group accounts means that 
the results can be independent of the location of the R&D activity. The Scoreboard indicates 
the level of R&D funded by companies, not all of which is carried out in the country in which 
the company is registered.  This enables inputs such as R&D and Capex investment to be 
related to outputs such as Sales, Profit, productivity ratios and market capitalisation.  
The data used for the Scoreboard are different from data provided by statistical offices, e.g. 
BERD data. The Scoreboard refers to all R&D financed by a particular company from its own 
funds, regardless of where that R&D activity is performed. BERD refers to all R&D activities 
performed by businesses within a particular sector and territory, regardless of the location of 
the business’s headquarters, and regardless of the sources of finance.  
Further, the Scoreboard  collects data from audited financial accounts and reports. BERD 
typically takes a stratified sample, covering all large companies and a representative sample 
of smaller companies. Additional differences concern the definition of R&D intensity (BERD 
uses the percentage of value added, while the Scoreboard measures it as the R&D/Sales 
ratio) and the sectoral classification they use (BERD follows NACE, the European statistical   
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classification of economic sectors, while the Scoreboard classifies companies’ economic 
activities according to the ICB classification). 
Sudden changes in R&D figures may arise because a change in company accounting 
standards. For example, the first time adoption of IFRS
23, may lead to information 
discontinuities due to the different treatment of R&D, i.e. R&D capitalisation criteria are 
stricter and, where the criteria are met, the amounts must be capitalised.  
For many highly diversified companies, the R&D investment disclosed in their accounts 
relates only to part of their activities, whereas sales and profits are in respect of all their 
activities. Unless such groups disclose their R&D investment additional to the other 
information in segmental analyses, it is not possible to relate the R&D more closely to the 
results of the individual activities which give rise to it. The impact of this is that some 
statistics for these groups, e.g. R&D as a percentage of sales, are possibly underestimated 
and so comparisons with non-diversified groups are limited. 
At the aggregate level, the growth statistics reflect the growth of the set of companies in the 
current year set. Companies which may have existed in the base year but which are not 
represented in the current year set are not part of the Scoreboard (a company may continue 
to be represented in the current year set if it has been acquired by or merged with another).  
For companies outside the Euro area, all currency amounts have been translated at the Euro 
exchange rates ruling at 31 December 2012 as shown in Table A3.1.The exchange rate 
conversion also applies to the historical data. The result is that over time the Scoreboard 
reflects the domestic currency results of the companies rather than economic estimates of 
current purchasing parity results. The original domestic currency data can be derived simply 
by reversing the translations at the rates above. Users can then apply their own preferred 
current purchasing parity transformation models.  
  
 
 
 
 
                                                       
23 Since 2005, the European Union requires all listed companies in the EU to prepare their consolidated financial statements 
according to IFRS (International Financial Reporting Standards, see: http://www.iasb.org/).   
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Glossary of definitions 
 
1.  Research and Development (R&D) investment in the Scoreboard is the cash investment 
funded by the companies themselves. It excludes R&D undertaken under contract for 
customers such as governments or other companies. It also excludes the companies' share of 
any associated company or joint venture R&D investment. Being that disclosed in the annual 
report and accounts, it is subject to the accounting definitions of R&D. For example, a 
definition is set out in International Accounting Standard (IAS) 38 “Intangible assets” and is 
Table A3.1.   Euro exchange rates applied to Scoreboard data of companies based in 
different currency areas (as of 31 Dec 2012). 
Country  As of 31 Dec 2011  As of 31 Dec 2012 
Australia  $ 1.2740  $ 1.27 
Brazil  2.4051 Brazilian real  2.69 Brazilian real 
Canada  $ 1.3210  $ 1.31 
China  8.1526 Renminbi  8.30 Renminbi 
Czech 
Republic 
25.7998 Koruna  25.14 Koruna 
Croatia  7.5370 Kuna  7.55 Kuna 
Denmark  7.4344 Danish Kronor  7.47 Danish Kronor 
Hungary  314.158 Forint  291.54 Forint 
India  68.9178 Indian Rupee  72.25 Indian Rupee 
Israel  4.9439 Shekel  4.92 Shekel 
Japan  100.6036  Yen  114.15  Yen 
Mexico  18.10 Mexican Peso  17.16 Mexican Peso 
Norway  7.750 Norwegian Kronor  7.35 Norwegian Kronor 
Poland  4.4218 Zloty  4.09 Zloty 
Russia  41.666 Rouble  40.08 Rouble 
South Korea  1492.54 Won  1408.45 Won 
Sweden  8.9119 Swedish Kronor  8.58 Swedish Kronor 
Switzerland  1.2174 Swiss Franc  1.21 Swiss Franc 
Turkey  2.450 Turkish lira  2.35 Turkish lira 
UK  £ 0.8368  £ 0.84 
USA  $ 1.2939  $ 1.32 
Taiwan  $ 39.1696  $ 38.28   
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based on the OECD “Frascati” manual. Research is defined as original and planned 
investigation undertaken with the prospect of gaining new scientific or technical knowledge 
and understanding. Expenditure on research is recognised as an expense when it is incurred. 
Development is the application of research findings or other knowledge to a plan or design 
for the production of new or substantially improved materials, devices, products, processes, 
systems or services before the start of commercial production or use. Development costs are 
capitalised when they meet certain criteria and when it can be demonstrated that the asset 
will generate probable future economic benefits. Where part or all of R&D costs have been 
capitalised, the additions to the appropriate intangible assets are included to calculate the 
cash investment and any amortisation eliminated. 
2.  Net sales follow the usual accounting definition of sales, excluding sales taxes and 
shares of sales of joint ventures & associates. For banks, sales are defined as the “Total 
(operating) income” plus any insurance income. For insurance companies, sales are defined 
as “Gross premiums written” plus any banking income. 
3.  R&D intensity is the ratio between R&D investment and net sales of a given company or 
group of companies. At the aggregate level, R&D intensity is calculated only by those 
companies for which data exist for both R&D and net sales in the specified year. The 
calculation of R&D intensity in the Scoreboard is different from than in official statistics, e.g. 
BERD, where R&D intensity is based on value added instead of net sales.  
4.  Operating profit is calculated as profit (or loss) before taxation, plus net interest cost (or 
minus net interest income) minus government grants, less gains (or plus losses) arising from 
the sale/disposal of businesses or fixed assets. 
5.  One-year growth is simple growth over the previous year, expressed as a percentage: 1 
yr growth = 100*((C/B)-1); where C = current year amount, and B = previous year amount. 
1yr growth is calculated only if data exist for both the current and previous year. At the 
aggregate level, 1yr growth is calculated only by aggregating those companies for which data 
exist for both the current and previous year. 
6.  Three-year growth is the compound annual growth over the previous three years, 
expressed as a percentage: 3 yr growth = 100*(((C/B)^(1/t))-1); where C = current year 
amount, B = base year amount (where base year = current year - 3), and t = number of time 
periods (= 3). 3yr growth is calculated only if data exist for the current and base years. At the 
aggregate level, 3yr growth is calculated only by aggregating those companies for which data 
exist for the current and base years. 
 
7.  Capital expenditure (Capex) is expenditure used by a company to acquire or upgrade 
physical assets such as equipment, property, industrial buildings. In accounts capital 
expenditure is added to an asset account (i.e. capitalised), thus increasing the asset's base. It 
is disclosed in accounts as additions to tangible fixed assets. 
8.  Number of employees is the total consolidated average employees or year end 
employees if average not stated. 
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Annex 3 – Composition of the top 1000 EU sample 
The analysis of chapter 5 applies an extended sample of 1000 companies based in the EU. It consists of 527 companies included in the world 
R&D ranking of top 2000 companies and additional 473 companies also ranked by level of R&D investment. The composition by country and 
industry of the EU 1000 sample is presented in the table A3.1 below. 
Table A3.1 Distribution of the sample of 1000 companies based in the EU by country and industry. 
Industry              EU country codes                                        
 (ICB-3D)  AT  BE  CZ  DE  DK  ES  FI  FR  UK  GR  HU  IE  IT  LU  MT  NL  PL  PT  SE  SI  Total 
Aerospace & Defence     1     2     1     6  8           2        1        1     22 
Alternative Energy           4  1                         1                    6 
Automobiles & Parts  4        20        1  6  11           6                 2     50 
Banks     2     6  2  1     1  5        1  2  1     3  1  2  3     30 
Beverages     1     1  1           1                    1              5 
Chemicals  1  3     12  1     3  4  11              1     3        3     42 
Construction & Materials  3  5     7  1  3  2  6  1        2  2        3        2  1  38 
Electricity     1  1  1     2  2  2  4           2              1  1     17 
Electronic & Electrical Equip.  3  4     16  2     5  12  18        1  4  1     6        4     76 
Equity Investment Instr.           1                                                 1 
Financial Services           4           1  6                    1        4     16 
Fixed Line Telecommunications  1  1     1  1  1     1  1           1        1  1  1  1     12 
Food & Drug Retailers     1                    2                    1              4 
Food Producers           2  1     4  3  8        3     1     5              27 
Forestry & Paper                    3  1  1                             4     9 
Gas, Water & Multi-utilities  1        3  1        2  3                                   10 
General Industrials     1     10  1  1  1  1  10           1        2        5     33 
General Retailers           4           1  6                                   11 
Health Care Equipment & 
Services     2     13  2        2  7        2  1        2        6     37 
Household Goods & Home 
Const.           5     1  1  2  3           3  1     1        2     19  
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Industry              EU country codes                                        
 (ICB-3D)  AT  BE  CZ  DE  DK  ES  FI  FR  UK  GR  HU  IE  IT  LU  MT  NL  PL  PT  SE  SI  Total 
Industrial Engineering  4  2     42  4  3  8  7  14        1  8  2     5        12     112 
Industrial Metals & Mining  2  2     5        2  1                2     1        1     16 
Industrial Transportation        1  1  1        3  1           2        1        2     12 
Leisure Goods           1  2     1     2                    1              7 
Life Insurance           1           1  2                                   4 
Media                       5  7           1                 1     14 
Mining           1              4                             2     7 
Mobile Telecommunications           1     1  1     3                                   6 
Nonlife Insurance  1        1              1                                   3 
Oil & Gas Producers  1              1  1  1  3           1                       8 
Oil Equipment, Services & 
Distrib.                       2                1     3              6 
Personal Goods  1        6           4             3  2                    16 
Pharmaceuticals & 
Biotechnology  1  4     13  13  4  2  18  29  1  1  4  5        3     1  11  1  111 
Real Estate Investment & 
Services           1           1                                     2 
Software & Computer Services  2        19  2  2  5  21  45           1        4  2  1  7     111 
Support Services           10           2  19        1           2        4     38 
Technology Hardware & Equip.  2  2     7  1  1  2  6  11  1     1           5        7     46 
Tobacco                          1                             1     2 
Travel & Leisure  1        3        1  1  4           1     1           2     14 
Total 28 32  2  224 37 22 45 124  252 2  1 16  46  13 1 55 4  6 88 2 1000 
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Annex 4 - Access to the full dataset 
 
 
The 2013 Scoreboard comprises two data samples: 
•  The world’s top 2000 companies that invested more than €22.6m in R&D in 
2012. 
•  The top 1000 R&D investing companies based in the EU with R&D 
investment exceeding €5.2m. 
  
For each company the following information is available:  
•  Company identification (name, country of registration and sector of 
declared activity according to ICB classifications). 
•  R&D investment  
•  Net Sales  
•  Capital expenditure  
•  Operating profit or loss  
•  Total number of employees 
•  Main company indicators (R&D intensity, Capex intensity, Profitability) 
•  Growth rates of main indicators over one year and three years. 
 
 
 
The following links provide access to the two Scoreboard data samples containing 
the main economic and financial indicators and main statistics over the past four 
years. 
 
 
R&D ranking of world top 2000 companies: 
http://iri.jrc.ec.europa.eu/documents/10180/cf102ca1-e554-46d2-b271-
1168e83a419c 
 
R&D ranking of EU top 1000 companies:  
http://iri.jrc.ec.europa.eu/documents/10180/64449b4f-9c6f-41a1-9dcc-
73183d84d17b 
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Abstract 
This report presents the results of the 2013 "EU Industrial R&D Investment Scoreboard" (the 
Scoreboard). The Scoreboard contains economic and financial data for the world's top 2000 companies 
ranked by their investments in research and development (R&D). The sample consists of 527 
companies based in the EU and 1473 companies based elsewhere. An additional sample comprising 
the top 1000 R&D investing companies based in the EU is included. The Scoreboard data are drawn 
from the latest available companies' accounts, i.e. usually the fiscal year 2012 or 2012/13. 
In this Scoreboard edition, world top R&D investors show a remarkable resilience of R&D investment 
growth in a period of economic uncertainty. In 2012, companies continued to increase significantly 
their R&D investments in a context marked by a slow-down of net sales growth and a decline in 
operating profits.   
Trends observed show a significant variation of R&D investment and economic results across industries 
and sectors. This reflects persistent market uncertainties, in particular regarding the uneven potential 
for growth of international markets and the macroeconomic background. 
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